NEW YORK, May 22, 2013 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Hemoglobin A1c Testing Markets
http://www.reportlinker.com/p01138843/Hemoglobin-A1c-Testing-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Hemoglobin A1c (HbA1c) testing is the most recent major technology to have entered the diabetes testing market. As the global prevalence of diabetes mellitus continues to increase rapidly, with more than 366 million diabetics worldwide, hemoglobin A1c testing is now an essential assay in the diabetes testing repertoire. Its clinical utility and improvements in its accuracy and implementation of standardized protocols have translated into continued market growth.

This TriMark Publications report describes the specific market segment that encompasses hemoglobin A1c testing for diagnosing and monitoring diabetes. The study reviews all of the generally accepted clinical analytical methods that are currently in use today for measuring HbA1c levels. Moreover, it examines clinical measurement devices and reagents as utilized in hospitals, clinics, doctor’s offices and at-home care locations. The report also analyzes almost all of the companies known to be marketing, manufacturing or developing hemoglobin A1c testing. Detailed tables and charts with sales forecasts and marketshare data are also included.

TABLE OF CONTENTS

1. Overview 6
1.1 Statement of Reprt 6
1.2 About this Report 7
1.3 Scope of the Report 7
1.4 Methodology 8
1.5 Executive Summary 9

2. Diabetes 12
2.1 Demographics of Diabetes 13
2.1.1 Worldwide Diabetes Incidence 13
2.1.2 Diabetes in the U.S. 16
2.2 Understanding the Metabolic Conditions Underlying and Associated with
Diabetes 19
2.2.1 Pre-Diabetes Syndrome 21
2.2.2 Metabolic Syndrome 21
2.2.3 Progression of Diabetes 21
2.2.4 Diabetes and Inflammation 21
2.2.5 Risk Factors and Diabetes 22
2.2.5.1 Obesity 23
2.2.5.2 Stress-Induced Hyperglycemia 25
2.2.6 Complications and Co-Morbidities in Diabetes 25
2.2.6.1 Preventing Complications and Co-Morbidities in Diabetes 28
2.2.6.2 Cardiovascular Disease Facts 30
2.3 Economics of Diabetes 33

3. Market Analysis: Size, Growth, Share and Competitors 38
3.1 Worldwide HbA1c Testing Market 39
3.1.1 U.S. HbA1c Testing Market 40
3.2 HbA1c Self-Testing Market 41
3.3 Competitive Situation 43
3.3.1 Analyses of the Key Players, Current Market Conditions, and Product Mix 43
3.3.2 Competitive Strategies and Strategic Recommendations 44
3.3.3 Future Competing Technologies—Glycated Albumin 45
3.4 Market Drivers and Restraints 46
3.4.1 Market Drivers 46
3.4.2 Market Restraints 46
3.5 Market and Product Trends 47
3.5.1 Increase in POC AC1 Testing 47
3.5.2 Move Towards Screening for Diabetes Using HbA1c Assays 48
3.6 Adjacent Markets 48

4. Overview of HbA1c Testing 49
4.1 Technology Platforms Used to Measure HbA1c 50
4.1.1 High-Performance Liquid Chromatography (HPLC) 50
4.1.2 Immunoassays 50
4.1.3 Boronate Affinity Chromatography 50
4.1.4 Enzymatic Assay 51
4.1.5 Micro-Optical Detection Methods 51
4.2 Development of HbA1c Testing: A Historical Evaluation 51
4.2.1 The Diabetes Control and Complications Trial (DCCT) 51
4.3 Standardization of HbA1c Testing and Certification Criteria 52
4.3.1 National Glycohemoglobin Standardization Program (NGSP) 52
4.3.2 International Federation of Clinical Chemistry (IFCC) 53
4.3.3 New NGSP Certification Criteria Beginning in September 53
4.3.4 ADAG (A1c Derived Average Glucose) 53
4.3.5 2010 Consensus Statement on the Worldwide Standardization of HbA1c 53
4.3.6 College of American Pathologists (CAP) Proficiency Program 54
4.3.7 Certifications and Selecting HbA1c Assays 54
4.4 Advantages and Disadvantages of HbA1c Assessment 54
4.5 HbA1c Testing Recommendations 56
4.5.1 Frequency of HbA1c Testing 56
4.5.2 Diagnostic HbA1c Testing 57
4.5.3 Screening for Pre-diabetes 59
4.5.4 HbA1c Testing for Diabetes Management and Glycemic Goals 59
4.6 Accuracy and Precision in HbA1c Testing 60
4.6.1 Biological Variation 60
4.6.2 Pre-Analytical Variation 61
4.6.3 Analytical Variation 61
4.7 Potential Interfering Variables Affecting HbA1c Testing 63
4.8 Potential Areas of Improvement in HbA1c Testing Performance 64
4.9 Optimizing of Point of Care (POC) HbA1c Testing 65
4.10 Key Issues for HbA1c Testing 65
4.11 HbA1c Testing and Blood Glucose Testing: Complementary Tools 66

5. HbA1c Testing Devices on the Market 68
5.1 HbA1c Self-Testing Devices 69
5.1.1 A1CNow SELFCHECK 69
5.1.2 DTI Laboratories, Inc. 69
5.1.3 Flexsite Diagnostics, Inc. 70
5.1.4 Heritage Labs International 70
5.2 Professional HbA1c Testing Devices 70
5.2.1 Point of Care HbA1c Testing 70
5.2.1.1 Axis-Shield (now part of Alere) 70
5.2.1.2 Bio-Rad 71
5.2.1.3 DiaSys Diagnostic Systems 71
5.2.1.4 Diazyme Laboratories 71
5.2.1.5 EKF Diagnostics 72
5.2.1.6 Infopia 72
5.2.1.7 Siemens Healthcare Diagnostics 72
5.2.2 HbA1c Laboratory Testing 73
5.2.2.1 Abbott 73
5.2.2.2 Arkray 73
5.2.2.3 Beckman Coulter 73
5.2.2.4 Bio-Rad 74
5.2.2.5 Diazyme Laboratories 75
5.2.2.6 EKF Diagnostics 75
5.2.2.7 Ortho Clinical Diagnostics (part of Johnson & Johnson) 75
5.2.2.8 Pointe Scientific, Inc. 75
5.2.2.9 Randox Laboratories 76
5.2.2.10 Roche 76
5.2.2.11 Siemens Healthcare Diagnostics 76
5.2.2.12 Tosoh 76
5.2.2.13 Trinity Biotech 77
5.3 New Product Innovations and Introductions 78
5.3.1 Trinity Biotech Launches the Premier Hb9210 78
5.3.2 Siemens Healthcare Announced a New Version of the DCA Vantage Analyzer 78
5.3.3 EKF Diagnostics to Launch the Quo-Lab HbA1c 78
5.3.4 Trivitron to Enter HbA1c Market 79
5.3.5 Tosoh Introduces the ST AIA-PACK HbA1c Assay 79
5.3.6 Tosoh Introduces a Comprehensive HbA1c Product Line 79
5.3.7 Axis-Shield Introduces the Afinion II 80
5.3.8 Infopia Obtains CE Certification of HbA1c Analyzer 80
5.3.9 Bio-Rad Introduces the in2it Analyzer 80
5.4 Recent Industry Activity & Corporate Developments 80
5.4.1 Axis-Shield Acquired by Alere 80
5.4.2 EKF Diagnostics Opens New Manufacturing Facility at its Quotient
Diagnostics Base 80
5.4.3 EKF Diagnostics Acquires Quotient Diagnostics 80
5.4.4 Beckman Coulter Acquires Olympus’ Lab-based Diagnostics Business 81
5.4.5 Trinity Biotech Acquires Primus Corporation 81
5.4.6 Geonostics Acquires FlexSite’s Diagnostics 81
5.4.7 Trinity Biotech Signs Distribution Agreements with Fisher and Menarini
Diagnostics 81
5.4.8 Bayer Divests Diagnostics Division to Siemens 81
5.4.9 Bayer Diabetes Care Acquires Metrika, Inc. 81
5.4.10 Sysmex America and Bio-Rad Sign Long-term Distribution Agreement 82

6. Business Trends in HbA1c Testing 83
6.1 Drivers and Trends of Clinical HbA1c Testing 83
6.2 Healthcare Cost Controls 83
6.3 Affordable Care Act Excise Tax on Medical Devices 83
6.4 Changes in Patient Management 84
6.5 Regionalization of Laboratory Care 84
6.6 Satellite Facilities 85
6.7 Point of Care Testing 86
6.7.1 Key Issues in the POC Diagnostic Testing Sector 86
6.7.2 Current Market Trends and Drivers 86
6.7.3 Effectiveness of POCT 89
6.7.4 Key Customer Segments 89
6.8 Factors Affecting OTC Medical Product Distribution 89
6.9 Drivers and Restraints of OTC and Self-Testing HbA1c Markets 91

7. Regulatory Environment and Insurance Reimbursements 92
7.1 U.S. Government Regulation of Medical Devices 92
7.2 FDA Labeling Requirements 93
7.3 Clinical Laboratory Improvement Act (CLIA) 93
7.4 HbA1c Testing Insurance Coverage and Reimbursement 96
7.5 Trends in U.S. Laboratory Testing Reimbursement Practices 97
7.6 Managed Care 98

8. Company Profiles 99
8.1 Abbott Laboratories 99
8.2 A. Menarini Diagnostics 102
8.3 Alere, Inc. 102
8.4 ARKRAY USA, Inc. 103
8.5 Axis-Shield Plc 103
8.6 Bayer Healthcare Diagnostics 104
8.7 Beckman Coulter , Inc 106
8.8 Bio-Rad Laboratories, Inc. 110
8.9 EKF Diagnostics 111
8.10 Infopia Co., Ltd. 112
8.11 Ortho Clinical Diagnostics (part of Johnson & Johnson) 112
8.12 Quotient Diagnostics 112
8.13 Randox Laboratories 113
8.14 Roche Diagnostics 113
8.15 Siemens AG 115
8.16 Tosoh Bioscience, Inc. 115
8.17 Trinity Biotech Plc 115

INDEX OF FIGURES

Figure 2.1: Worldwide Diabetes Cases, 2011 and 2030 13
Figure 2.2: Worldwide Prevalence of Diabetes (%) in Adults (20-79 Years), 2011
14
Figure 2.3: Prevalence of Diabetes by Age in the U.S., 2010 17
Figure 2.4: New Cases of Diabetes Diagnosed in the U.S. Adult Population, 2010
17
Figure 2.5: County-specific Diabetes Prevalence in the U.S., 2008 18
Figure 2.6: Maintenance of Normal Blood Sugar Levels 20
Figure 2.7: Obesity (BMI =30) Prevalence in U.S. Adults, 2010 23
Figure 2.8: Percentage of Obese Adults in the U.S., 2009-2010 24
Figure 2.9: Percentage of Obese Children and Adolescents in the U.S., 2009-2010
24
Figure 2.10: Trends in Obesity Among Children and Adolescents in the U.S.,
1963-2008 25
Figure 2.11: Relative Risk of Diabetes Complications by Mean HbA1c 27
Figure 2.12: Mean Diabetes Healthcare-related Expenditures Per Adult (20-79
Years) with
Diabetes (USD), 2011 34
Figure 3.1: Worldwide HbA1c Testing Market, 2008-2017 40
Figure 3.2: U.S. HbA1c Testing Market, 2008-2017 41
Figure 3.3: Global HbA1c Self-Testing Market, 2008-2017 42
Figure 4.1: Non-Enzymatic Glycation of Hemoglobin 49
Figure 4.2: Boronate Affinity Binding of Glycated Protein 51
Figure 4.3: Comparison of HbA1C and Blood Glucose Measurements over a Four-Day
Period 55
Figure 4.4: Range of Variation in HbA1c Assay 62
Figure 4.5: Range of Variation in the FPG Assay 62
Figure 7.1: CLIA Laboratories by Certificate Types 94

INDEX OF TABLES

Table 2.1: Regional Estimates of the Number of Diabetes (20-79 Years), 2011 and
2030 14
Table 2.2: Countries with the Largest Numbers of Diabetics, 2011 15
Table 2.3: Countries with the Largest Estimated Numbers of Diabetics, 2030 15
Table 2.4: Worldwide Undiagnosed Diabetes in Adults (20-79 Years) by Region and
Income Group, 2011 16
Table 2.5: U.S. Population of Diabetics (Diagnosed and Undiagnosed) Aged 20
Years or Older, 2010 17
Table 2.6: U.S. Incidence of Diagnosed Diabetes by Age, 2009 19
Table 2.7: Ten Leading Diagnoses for Co-Morbid Chronic Diseases in the U.S. 26
Table 2.8: Odds Ratio of Progression to Complications Associated with Type 2
Diabetes 27
Table 2.9: Prevalence of Complications Among Patients with Diabetes 27
Table 2.10: Novel Risk Factors and Possible Mechanisms of the Excess Risk of
Coronary Heart Disease in Type 2 Diabetes Mellitus 28
Table 2.11: Major Causes of End-Stage Renal Disease 28
Table 2.12: Clinical Recommendations for Adults with Diabetes 29
Table 2.13: Laboratory Assessment of Diabetic Vascular Disease 29
Table 2.14: Average Years Gained Free of Diabetes-related Disease with Intensive
Management 29
Table 2.15: Estimated Direct and Indirect Costs of Major Cardiovascular Diseases
and
Stroke in the U.S., 2008 31
Table 2.16: Worldwide Market for Cardiac Care Therapeutics, 2003-2010 31
Table 2.17: Top 20 Drugs for 2010 by U.S. Sales 32
Table 2.18: Cost of Diagnosed Diabetes in the U.S., 2007 34
Table 2.19: Medical Care Costs Attributable to Diabetes in the U.S., 2010 35
Table 2.20: Healthcare Utilization by Diabetic Patients, 2008 35
Table 2.21: Per-Event Costs of Diabetes Complications 36
Table 2.22: Annual Cost of Care of United Healthcare Adult Members with
Diabetes, 2009 36
Table 3.1: Worldwide HbA1c Testing Market, 2008-2017 39
Table 3.2: U.S. HbA1c Testing Market, 2008-2017 41
Table 3.3: Global HbA1c Self-Testing Market, 2008-2017 42
Table 3.4: Key Players in the HbA1c Clinical Laboratory Market 43
Table 3.5: Key Players in the HbA1c POC Market 44
Table 3.6: Key Players in the HbA1c Self-Testing Market 44
Table 3.7: Key Market Drivers for HbA1c Testing 46
Table 4.1: Summary of the 2010 Consensus Statement on the Worldwide
Standardization of HbA1c 53
Table 4.2: Advantages of HbA1c versus Blood Glucose Testing 55
Table 4.3: Disadvantages of HbA1c versus Blood Glucose Testing 56
Table 4.4: HbA1c Testing Recommendations 56
Table 4.5: Criteria for the Diagnosis of Diabetes 57
Table 4.6: Categories of Increased Risk for Diabetes (Pre-Diabetes) 57
Table 4.7: Glycemic Recommendations for Non-Pregnant Adults with Diabetes 59
Table 4.8: Glycemic Recommendations for Women with Gestational Diabetes 60
Table 4.9: Glycemic Recommendations for Pregnant Women with Pre-existing
Diabetes 60
Table 4.10: Conditions Known to Interfere with HbA1c Assays 63
Table 4.11: Interference from Hb Variants in Select HbA1c Testing Systems 64
Table 4.12: History of NGSP Manufacturer Certification Criteria 65
Table 4.13: Correlation of HbA1c with Mean Blood Glucose 67
Table 5.1: HbA1c Testing Devices and Assays on the Market 68
Table 7.1: Financial Comparison for Moderate and Waived CLIA Labs 95

To order this report:
: Hemoglobin A1c Testing Markets

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

RELATED LINKS
http://www.reportlinker.com

FREEHOLD, N.J., May 22, 2013 /PRNewswire/ — UMH Properties, Inc. (NYSE: UMH) will present at the NAREIT REITWeek 2013 Investor Forum to be held in Chicago, Illinois, at the Hilton Chicago.  The senior management of UMH Properties is scheduled to present on Wednesday, June 5, 2013, at 11:00 AM CDT. 

A copy of the presentation materials will be available following the forum on the Company’s investor relations website at http://ir.umh.com (select the Home tab, then Presentations and Documents).

UMH, which was organized in 1968 and operating as a publicly-owned REIT since 1985, owns and operates sixty-eight manufactured home communities containing approximately 12,800 developed home sites.  These communities are located in New Jersey, New York, Ohio, Pennsylvania, Tennessee, Indiana and Michigan.  In addition, the Company owns a portfolio of REIT securities.

SOURCE UMH Properties, Inc.

AUBURN HILLS, Mich., May 22, 2013 /PRNewswire/ – In the wake of the devastating tornado that hit Oklahoma earlier this week, The Chrysler Foundation, the charitable arm of Chrysler Group LLC, today announced that it will provide $100,000 to First Response Team of America (http://firstresponseteam.org), a nonprofit disaster relief organization which assists local first responders with rescues and also provides help with cleanup efforts. 

“We know that the road to recovery for the residents of Moore and Oklahoma City will be long,” said Reid Bigland , President and Chief Executive Officer – Ram Truck Brand, Chrysler Group LLC. “The Chrysler Foundation is proud to support First Response Team of America’s efforts to help the people of Oklahoma get back on their feet.” The Ram Truck brand has an existing relationship with First Response Team of America, including donating three heavy-duty trucks to support their efforts.

First Response Team of America goes from disaster to disaster lending a hand and assisting with rubble and water rescues and cleanups, clearing roads, creating a way into the community by removing debris and pumping out floodwaters, powering up emergency rooms, nursing homes and shelters and clearing home sites for those without insurance. The team tracks weather conditions so it is positioned to be nearby and ready to assist when disaster strikes. The team’s heavy equipment includes Ram trucks, multi terrain loaders, cranes, lighting towers, plasma cutters and a hovercraft for water rescues.

Last year, the Ram Truck brand announced a partnership with The Weather Channel Companies (TWCC) and First Response Team of America. Sponsored by the Ram Truck brand, TWCC launched an exclusive cross-platform series of in-the-field “Responding by Storm” reports chronicling the works of the First Response Team of America. 

“Our thoughts and prayers are with the people of Oklahoma,” said Jody Trapasso , President – The Chrysler Foundation. “We are heartened by their unwavering spirit during this difficult time and we are humbled to support the relief and recovery efforts.”

Chrysler Group and its brands have a long history of supporting its communities in their time of need. In the wake of last year’s Superstorm Sandy, the Ram Truck brand donated 20 Ram 1500 Tradesman trucks and $100,000 to the American Red Cross.

About Ram Truck Brand
The Ram Truck brand continues to establish its own identity and clearly define its customer since its launch as a standalone vehicle brand. Creating a distinct brand for Ram trucks has allowed the brand to concentrate on how core customers use their trucks and what new features they’d like to see. Whether focusing on a family that uses its half-ton truck day in and day out, a hard-working Ram Heavy Duty owner or a business that depends on its commercial vehicles every day, Ram has the truck market covered.

The Ram Truck brand has the most innovative lineup of full-size trucks on the market. Ram Truck has emerged as a full-size truck leader by investing substantially in new products, infusing them with great looks, refined interiors, durable engines and features that further enhance their capabilities. Truck customers, from half-ton to commercial, have a demanding range of needs and require their vehicles to provide high levels of capability. Ram trucks are designed to deliver a total package.

About The Chrysler Foundation
The Chrysler Foundation, the charitable arm of Chrysler Group LLC, has established a proud legacy of empowering people in the communities where we live and work. The Chrysler Foundation focuses on four key areas through its grant application process and volunteer activities: Education: K-12 and post-secondary education initiatives that encourage the study and pursuit of careers in business, design, science, technology, engineering, mathematics or supply-chain management; Military: support for our nation’s service members and their families in need; Multicultural / Diversity: initiatives that promote inclusion and advancement opportunities for diverse populations; and Youth Development: organizations and programs that provide mentoring and related assistance to aid youth in the transition to adulthood.

Since its inception in 1953, The Chrysler Foundation has awarded more than $500 million in charitable grants.

 

SOURCE Chrysler Group LLC

RELATED LINKS
http://www.chryslergroupllc.com

NEW YORK, May 22, 2013 /PRNewswire/ – As a small business owner, you can never underestimate the importance of customer loyalty and retention; both can be considered the backbone for any content marketing strategy.  Building customer trust through your business’ site can prove difficult if your content isn’t conveying the right message and doesn’t engage your target audience.

(Logo: http://photos.prnewswire.com/prnh/20110831/NY59180LOGO )
(Logo: http://photos.prnewswire.com/prnh/20130117/NY44355LOGO-a )

Founder of Interact Media and contributing author, Steve Lazuka , believes that without great web content your site will struggle to attract quality traffic, generate leads and make sales. In the latest article on PR Newswire’s PR Toolkit, Lazuka provides four elements of content that help to provide value and build trust with your customer base. 

To read the complete article visit: http://bit.ly/11bVL78.

PR Newswire’s PR Toolkit is a comprehensive resource that provides small businesses and entrepreneurs the tools to develop an affordable public relations & marketing plan that helps them increase search engine rankings, generate interest from potential customers, engage with key audiences and grow their businesses.  The toolkit features relevant content such as informative white papers, interactive webinars and how-to articles and premium access to educational resources, as well as the opportunity to take advantage of special offers designed specifically for small businesses. To request information on how PR Newswire can help your small business, click here. You can receive updates on new PR Toolkit content by following @prnsmallbiz on Twitter.

About PR Newswire                                   

PR Newswire (www.prnewswire.com) is the premier global provider of multimedia platforms that enable marketers, corporate communicators, sustainability officers, public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry 59 years ago, PR Newswire today provides end-to-end solutions to produce, optimize and target content — from rich media to online video to multimedia — and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world’s largest multi-channel, multi-cultural content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire enables the world’s enterprises to engage opportunity everywhere it exists. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a UBM plc company.

 

SOURCE PR Newswire Association LLC

RELATED LINKS
http://www.prnewswire.com

HAMDEN, Conn., May 22, 2013 /PRNewswire/ – Two current Pratt & Whitney employees and one retired Pratt & Whitney employee will be inducted into The Connecticut Academy of Science and Engineering at a ceremony this evening at Quinnipiac University in Hamden, Conn. Dr. Alan H. Epstein , vice president, Technology and Environment, Pratt & Whitney; Dr. David U. Furrer , senior fellow discipline lead, Materials and Processes Engineering, Pratt & Whitney; and Allan J. Brockett , former vice president, Engineering-Module Centers, Pratt & Whitney, will join an additional 30 new members of Connecticut‘s leading experts in science, engineering and technology. Pratt & Whitney is a United Technologies Corp. (NYSE: UTX) company.

According to the Academy, members are elected based on scientific and engineering distinction achieved through significant contributions in theory or applications, as demonstrated by original published books and papers, patents, the pioneering of new and developing fields and innovative products, outstanding leadership of nationally recognized technical teams, and external professional awards in recognition of scientific and engineering excellence.

“We congratulate Alan, David and Allan for their exceptional impact and hard work over the years in the design and engineering of game-changing technology, such as Pratt & Whitney’s PurePower® Geared Turbofan™ engine and F135 engine program,” said Tom Prete , vice president, Engineering, Pratt & Whitney. “Pratt & Whitney will never stop pioneering and improving commercial and military aviation engine technology, and this continued industry recognition of our employees communicates that steadfast dedication and innovative spirit.”

The Pratt & Whitney engineers are being recognized for the following achievements:

Dr. Epstein: For directing and coordinating technology across the company as it applies to product performance and environmental impact. For example, Epstein’s innovative ideas include game-changing developments for the company’s PurePower® Geared Turbofan™ engine that slashes fuel burn, gate-to-gate, by up to 16 percent and reduces aircraft engine noise pollution by up to 75 percent. Epstein holds a Bachelor of Science, Master of Science and PhD in Aeronautics and Astronautics from MIT. He holds numerous patents and has published more than 100 academic articles.

Dr. Furrer: For the development and application of materials and process modeling to support component design optimization. He has also written a number of papers and led a number of symposia in the area of Integrated Computational Materials Engineering (ICME).

Mr. Brockett: For his outstanding technical contributions to advanced military and commercial gas turbine engine technologies. For example, Brockett is responsible for developing advanced technologies associated with the F135 engine, which is exclusive power for the U.S. F-35 Lightning II. Brockett is also a 2011 recipient of the Distinguished Engineering Service Award from the University of Connecticut School of Engineering. 

The Connecticut Academy of Science and Engineering is a private, nonprofit, public-service institution patterned after the National Academy of Sciences. The Academy identifies and studies issues and technological advances that are or should be of concern to the people of Connecticut, and provides unbiased, expert advice on science- and technology-related issues to state government and other Connecticut institutions. It is comprised of distinguished scientists and engineers from Connecticut‘s academic, industrial, and institutional communities. Membership is limited by the Academy’s Bylaws to 400 members.

The Connecticut Academy of Science and Engineering was chartered by the Connecticut General Assembly in 1976 to provide expert guidance on science and technology to the people and to the state of Connecticut, and to promote the application of science and technology to human welfare and economic well-being. For more information about the Academy, please see www.ctcase.org.

Pratt & Whitney is a world leader in the design, manufacture and service of aircraft engines, auxiliary and ground power units and small turbojet propulsion products. United Technologies Corp., based in Hartford, Connecticut, is a diversified company providing high technology products and services to the building and aerospace industries. To learn more about UTC, visit the website or follow the company on Twitter: @UTC.

For more information, go to www.pw.utc.com
Facebook: www.facebook.com/prattandwhitney
Twitter: www.twitter.com/prattandwhitney
YouTube: http://www.youtube.com/prattandwhitney1925

SOURCE Pratt & Whitney

RELATED LINKS
http://www.pw.utc.com

NEW YORK, May 22, 2013 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Alzheimer`s Disease Therapeutics and Diagnostics: Global Markets
http://www.reportlinker.com/p0170505/Alzheimer`s-Disease-Therapeutics-and-Diagnostics-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics

STUDY GOALS AND OBJECTIVES

BCC’s goal in conducting this study was to determine the current status of Alzheimer’s disease treatments and diagnostics and assess the growth potential of this area over a 5-year period, from 2012 to 2017.

Our key objective was to present a comprehensive analysis of the current pipeline of therapeutic and diagnostic technologies, analyze the market and forecast for Alzheimer’s therapeutics and diagnostics, along with outlining the key factors that will influence this therapeutic area in the next few years.

REASONS FOR DOING THIS STUDY

Alzheimer’s disease is becoming an increasingly difficult challenge to caregivers, families and the healthcare industry as the number of patients climb and the frustration with lack of effective treatments grows. Though there are a number of marketed drugs approved for AD, this remains a significant area of unmet medical need. Clinical success has proven elusive; however, there are now numerous companies developing novel treatments. This report will review the programs in development and quantify the market opportunities in AD. This study aims to quantify where this market is heading and where the opportunities may lie.

SCOPE OF REPORT

The scope of this report is on the pharmaceutical segment, diagnostics and imaging modalities. We have compiled a study of the market, and current and emerging modes of treatment. We present the market segment’s economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for 2012 to 2017. We also project usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients, and the medical community. It will be of interest also to suppliers of products and services to this market area.

INTENDED AUDIENCE

The intended audience for this report is the pharmaceutical and biotechnology industries and diagnostics, as well as the medical industry that treats patients in these areas.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this research report. We present an analysis, by each disease area, of the number of current patients. Then, based on our surveys, we analyze the potential applications for pharmaceuticals, and forecast markets for 2012 through 2017.

INFORMATION SOURCES

BCC surveyed approximately 50 companies to obtain data for this study. Included were drug development and diagnostics companies and medical professionals. We also spoke with patients affected by memory and cognition diseases. In addition, we compiled data from current financial and trade information, and government sources.

ANALYST CREDENTIALS

Yogita Zutshi has 14 years of industry experience working in the areas of clinical and market research in the pharmaceutical area. She has an MS in Organic Chemistry, an MS in Clinical Research and a Bachelor’s in Education. She has also worked on research projects in clinical data management, and developed training modules for the clinical and pharmacovigilance areas.

REPORT HIGHLIGHTS

This report provides:

• An overview of the global market for Alzheimer’s disease therapeutic and diagnostic technologies
• Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
• Review of programs in development and quantification of market opportunities
• Discussion of the market segments’ economic environment, technological descriptions and issues, and applications
• Projections of usage in the major primary and secondary disease application areas
• Comprehensive company profiles of major players in the industry.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 2
METHODOLOGY 2
INFORMATION SOURCES 3
ANALYST CREDENTIALS 3
RELATED BCC REPORTS 3
BCC ONLINE SERVICES 3
DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY 6
SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER’S DISEASE, THROUGH 2017 ($
MILLIONS) 6
SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER’S DISEASE, 2011-2017 ($
MILLIONS) 7
FORECAST SUMMARY 7
DRIVERS FOR THE ALZHEIMER’S DISEASE MARKET 8
BARRIERS FOR THE ALZHEIMER’S DISEASE MARKET 8

CHAPTER 3 OVERVIEW 10

DEFINITION AND MARKET STRUCTURE 10
WHAT IS ALZHEIMER’S DISEASE? 10
TABLE 1 U.S. ALZHEIMER’S PATIENTS, 2002-2050 (MILLIONS) 10
FIGURE 1 U.S. ALZHEIMER’S PATIENTS, 2002-2050 (MILLIONS) 10
Role of the Cholinergic System 11
Role of Beta-Amyloid Protein 11
Behavioral Manifestations of AD 12
INCIDENCE AND PREVALENCE 13
TABLE 2 POPULATION BY SELECTED GEOGRAPHIC REGION, 2011-2050 (MILLIONS) 13
TABLE 3 PERCENT POPULATION OVER 65 BY REGION, 2011 (%) 13
TABLE 4 PEOPLE WITH ALZHEIMER’S DISEASE BY AGE GROUP, 2004-2050
(MILLIONS) 14
FIGURE 2 PEOPLE WITH ALZHEIMER’S DISEASE BY AGE GROUP 2004-2050 14
TABLE 5 PERCENTAGE OF PEOPLE WITH ALZHEIMER’S, BY AGE BRACKET, 60-94 (%) 14
FIGURE 3 PERCENTAGE OF PEOPLE WITH ALZHEIMER’S, BY AGE BRACKET, 60-94
(%) 14
TABLE 6 GLOBAL DISEASE PREVALENCE: ALZHEIMER’S DISEASE (%) 15
STAGES OF ALZHEIMER’S DISEASE 15
The Seven Stages 16
No Cognitive Decline 16
Very Mild Cognitive Decline (Occasionally Referred to as Mild
Cognitive Impairment) 16
Mild Cognitive Decline (Early Confused Stage): Losses or
Changes in the Ability to: 16
Moderate Cognitive Decline (Late Confusional Stage): 16
Moderately Severe Cognitive Decline (Early Dementia Phase): 17
Severe Cognitive Decline (Dementia): 17
Very Severe Cognitive Decline (Late Dementia or End Stage): 17
DIAGNOSIS 18
TABLE 7 DIAGNOSTIC TESTS 18
Exit 25 (Executive Interview) 19
Clock Drawing Test (CDT) 19
Urinalysis 19
Dipsticks Used in Urinalysis 20
Functional Assessment Staging Test (Fast) 20
EP-AD 20
How Accurate are the Screening Tests? 20
KEY EVENTS 22
PATENT EXPIRATIONS 22
NEW PRODUCT LAUNCHES 22
PRICING 22
KEY MARKETS 22
TABLE 8 GLOBAL MARKET FOR ALZHEIMER’S DISEASE BY REGION, THROUGH 2017
($ MILLIONS) 23
FIGURE 4 GLOBAL MARKET FOR ALZHEIMER’S DISEASE, BY REGION, 2011-2017 ($
MILLIONS) 23
MARKET SIZE AND KEY PLAYERS 23
Therapeutics 24
TABLE 9 EXISTING TREATMENTS FOR ALZHEIMER’S DISEASE 24
TABLE 10 GLOBAL EXISTING MARKET FOR SYMPTOM-ADDRESSING ALZHEIMER’S
DISEASE BY TYPE, 2010-2017 ($ MILLIONS) 25
TABLE 11 ESTIMATED GLOBAL MARKET FOR ALZHEIMER’S DRUG CLASSES BY
GEOGRAPHICAL REGION (U.S., EUROPE, JAPAN, OTHERS), 2012 ($ MILLIONS) 25
TABLE 12 TYPES OF DRUGS USED TO TREAT ALZHEIMER’S DISEASE 26
TABLE 13 MARKET SHARE OF EXISTING THERAPEUTICS FOR ALZHEIMER’S DISEASE,
2011 (%) 26
TABLE 14 BREAKDOWN OF TREATMENT MARKET BY DISEASE SEVERITY (%) 27
TABLE 15 DEMENTIA RATE BY UNDERLYING DISEASE (%) 27
TABLE 16 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%) 27
TABLE 17 GLOBAL TREATMENT OF ALZHEIMER’S DISEASE, THROUGH 2017 ($
MILLIONS) 28
FIGURE 5 GLOBAL TREATMENT OF ALZHEIMER’S DISEASE, 2010-2017 ($ MILLIONS) 28
TABLE 18 GLOBAL POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS,
THROUGH 2017 ($ MILLIONS) 29
FIGURE 6 GLOBAL MEMORY/COGNITION THERAPEUTICS MARKET BY DISEASE AREA,
2011 (%) 29
KEY PLAYERS 30
TABLE 19 MARKET SHARE OF TOP COMPANIES WORKING IN MEMORY AND
COGNITION (%) 30
TABLE 20 MARKETED TREATMENTS FOR ALZHEIMER’S DISEASE 31
DRIVERS 31
ISSUES AND CHALLENGES 31
IMAGING AND DIAGNOSTICS 32
Current Use in Alzheimer’s Disease 32
Diagnostic Testing Segments 33
Imaging 33
TABLE 21 IMAGING MARKET, 2012 ($ MILLIONS) 33
FIGURE 7 IMAGING MARKET, 2012 ($ MILLIONS) 34
Standardization Needed 34
Diagnostics 35
Novel Imaging Agents 36
Opportunities for Biomarkers in AD 36
TABLE 22 BIOMARKERS FOR ALZHEIMER’S DISEASE 37
TABLE 23 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, THROUGH 2017
($ MILLIONS) 38
FIGURE 8 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, 2011-2017 ($
MILLIONS) 39
Testing Hypotheses 41
DIAGNOSTIC TESTS 41
KEY PLAYERS 42
AGILENT TECHNOLOGIES 42
BIOSCAN 43
CAPINTEC INC. 43
DIGIRAD CORPORATION 43
GAMMA MEDICA-IDEAS 43
GE HEALTHCARE 44
HITACHI MEDICAL SYSTEMS AMERICA INC. 44
NYMOX 44
OPTOSONICS INC. 45
PHILIPS HEALTHCARE 45
POSITRON CORP. 46
SIEMENS HEALTHCARE 46
SPECTRUM DYNAMICS LTD. 46
TOSHIBA MEDICAL SYSTEMS 47
ULTRASPECT LTD. 47
VISEN MEDICAL INC. 47
ZECOTEK IMAGING SYSTEMS 48
DRIVERS 48
ISSUES AND CHALLENGES 48
SWOT ANALYSIS 49
TABLE 24 SWOT ANALYSIS OF EXISTING ALZHEIMER’S DISEASE MARKET AND
PLAYERS 49

CHAPTER 4 TECHNOLOGIES AND APPLICATIONS 51

COMMON MECHANISMS OF ACTION 51
CHOLINESTERASE INHIBITORS 51
TABLE 25 CHOLINESTERASE INHIBITORS 52
TABLE 26 PRODUCT SIDE EFFECT COMPARISON (%) 53
FIGURE 9 PRODUCT SIDE EFFECT COMPARISON (%) 53
TABLE 27 VACCINES 54
TABLE 28 ANTI-OXIDANTS 54
NMDA ANTAGONISTS 54
TABLE 29 NMDA ANTAGONISTS 54
NICOTINICS 55
TABLE 30 NICOTINIC ACETYLCHOLINE ANTAGONISTS 55
CALCINEURINS 55
TABLE 31 CALCINEURINS 56
GABA MODULATORS 56
TABLE 32 ANTI-EPILEPTIC/GABA MODULATORS 56
HORMONES 57
TABLE 33 HORMONES 57
OTHER THERAPEUTIC MECHANISMS 57
TABLE 34 OTC TREATMENTS/NATURAL PRODUCTS 58
IMAGING AND DIAGNOSTICS: MODALITIES AND APPLICATIONS 58
NUCLEAR MEDICINE 59
POSITRON EMISSION TOMOGRAPHY (PET) 60
SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) 61
GAMMA CAMERAS 61
CT (COMPUTED TOMOGRAPHY) 61
DEXA 61
MRI (MAGNETIC RESONANCE IMAGING) 62
ULTRASOUND 63
X-RAY 63
FUSION IMAGING 64
PET/CT 64
SPECT-CT 65
SPECT-CT in Cardiology 65
SPECT-CT in General Nuclear Medicine 66
SPECT-CT in Neurology 66
DIAGNOSTIC IMAGING IN ALZHEIMER’S 66
DISEASE-MODIFYING VS. TREATMENT OF SYMPTOMS 66
SYMPTOMATIC RELIEF-LIFE-CYCLE MANAGEMENT OF EXISTING PRODUCTS 67
OTHER DRUGS TARGETING SYMPTOMATIC RELIEF 67
DRUG RE-PURPOSING 68
GENERICS 68

CHAPTER 5 WORLDWIDE INDUSTRY STRUCTURE 70

GROWTH DRIVERS 70
AGING POPULATION 70
OFF-LABEL USE 70
UNDERSTANDING OF MECHANISMS 71
TRANSCRANIAL MAGNETIC STIMULATION 72
GENETIC MODIFICATIONS 72
GROWTH OBSTACLES 72
UNDERSTANDING OF MECHANISM 73
TABLE 35 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 73
CO-MORBID DISEASE STATES 73
KEY COMPETITIVE FACTORS 73
PRODUCT LAUNCH 74
LIFE CYCLE MANAGEMENT 74
PAYERS 74
INTERNATIONAL ASPECTS 75
TABLE 36 PERCAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY,
THROUGH 2010 ($ MILLIONS) 76

CHAPTER 6 LEGISLATION AND REGULATORY ENVIRONMENT 79

VALIDATED TARGETS 79
LACK OF BIOMARKERS 79
TRANSLATIONAL MEDICINE 80
REIMBURSEMENT 80

CHAPTER 7 RELATED DEALS AND PARTNERSHIPS 83

APPROACH 83
DIAGNOSTICS DEALS 83
OVERALL ACTIVITY 84
TABLE 37 DEALS AND PARTNERSHIPS, 2005-2012 84

CHAPTER 8 PIPELINE 88

TABLE 38 DEVELOPMENT PIPELINE OF ALZHEIMER’S DRUGS, BY PHASE 89
FIGURE 10 DEVELOPMENT PIPELINE OF ALZHEIMER’S DRUGS: NUMBER OF
PROGRAMS AT EACH CLINICAL PHASE 95

CHAPTER 9 TRENDS AND CHALLENGES 98

AWARENESS OF ALZHEIMER’S 98
DISEASE PATHWAYS BEING ELUCIDATED 98
MANY PROGRAMS IN DEVELOPMENT 98
TABLE 39 SOME NOT-FOR-PROFIT ORGANIZATIONS AND CONSORTIA IN THE AD
AREA 99
TABLE 40 INVESTMENT IN ALZHEIMER’S DISEASE COMPANIES, 2008-2012 101

CHAPTER 10 OUTLOOK 104

A VARIETY OF APPROACHES IN RESEARCH 104
MANY PROGRAMS IN DEVELOPMENT 105

CHAPTER 11 PATENT ANALYSIS 107

TABLE 41 KEY PATENT EXPIRY: ALZHEIMER’S THERAPEUTICS, BY CATEGORY
THERAPEUTICS AND TECHNOLOGIES 107
TABLE 42 MAJOR U.S. PATENT HOLDERS/FILERS IN ALZHEIMER’S 108
TABLE 43 PATENTS ISSUED, 2011-2012 108
TABLE 44 PATENT APPLICATIONS 128

CHAPTER 12 COMPANY PROFILES 149

ABBOTT LABORATORIES 149
ABLYNX 149
ACCERA, INC. 149
ACUMEN PHARMACEUTICALS 152
ADAMAS PHARMACEUTICALS 152
AFFIRIS AG 153
AFFITECH AS 153
ALLON THERAPEUTICS (FKA NEURODISCOVERY) 154
ALZHYME PTY 154
ASTELLAS 154
ASTRAZENECA 155
ATHENA DIAGNOSTICS ( THERMO FISHER ) 155
AVERA PHARMACEUTICALS 156
BAXTER INTERNATIONAL INC. (BAXTER) 156
BAYER HEALTHCARE PHARMA 157
BELLUS HEALTH 157
BIOFUTURA 158
BIOMERIEUX 158
BIOVAIL 158
BOEHRINGER INGELHEIM 159
BRACCO 159
BRAINCELLS, INC. 159
BRISTOL MYERS SQUIBB 159
CELLZOME 160
CEREGENE 160
COGNITION PHARMACEUTICALS LLC 160
COGNITION THERAPEUTICS 161
COLUCID PHARMACEUTICALS 161
COMENTIS 161
CORTEX PHARMACEUTICALS 162
C2N DIAGNOSTICS 162
CYTOS BIOTECHNOLOGY 162
DAIICHI SANKYO 163
DEBIOPHARM 163
DURECT 163
EISAI 164
ELAN 165
ELI LILLY 165
ENVIVO PHARMACEUTICALS 165
ESTEVE 166
EVOTEC 166
EXONHIT THERAPEUTICS 167
FOREST LABORATORIES 167
GALANTOS PHARMA 168
GALENEA 168
GE HEALTHCARE 168
GLAXOSMITH KLINE 169
HELICON THERAPEUTICS 169
INTELLECT NEUROSCIENCES 169
INTRA-CELLULAR THERAPIES 170
INVERNESS MEDICAL INNOVATIONS 170
IPSEN 171
JOHNSON & JOHNSON 171
KEYNEUROTEK 172
LEXICON PHARMACEUTICALS 172
LINK MEDICINE 172
LUNDBECK 173
MEDIVATION 173
MEMORY PHARMACEUTICALS 174
MERCK 174
MERCKSERONO 174
MERZ PHARMA 175
MITHRIDION 175
MITSUBISHI TANABE 175
MORPHOSYS 176
NEUREN PHARMACEUTICALS 176
NEUROPTIX (COGNOPTIX, INC) 177
NEUROSEARCH 177
NEURO-HITECH 178
NEWRON PHARMACEUTICALS 178
NOSCIRA SA 178
NOVARTIS AG 179
NYMOX 179
OLIGOMERIX 180
ORTHO-MCNEIL NEUROLOGICS 180
PFIZER 180
POWER3 MEDICAL PRODUCTS 181
PRANA BIOTECHNOLOGY 182
PROTEOTECH INC. 182
PSYCHOGENICS 182
ROCHE 183
REPROCELL 183
SAMARITAN PHARMACEUTICALS 184
SANOFI-AVENTIS 184
SATORI PHARMACEUTICALS 184
SATORIS 185
SCIELE PHARMA 185
SIEMENS MEDICAL SOLUTIONS 186
SOLVAY 186
SUVEN LIFE SCIENCE 186
TAKEDA 187
TARGACEPT 187
TAURX THERAPEUTICS 187
TAUTATIS 188
TEIKOKU 188
TEVA PHARMACEUTICALS 189
TRANSTECH PHARMA 189
VALEANT PHARMACEUTICALS 190
VOYAGER PHARMACEUTICAL / DURAMED 190
WATSON PHARMACEUTICALS 190
WYETH/PFIZER 190

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER’S DISEASE, THROUGH 2017 ($
MILLIONS) 6
TABLE 1 U.S. ALZHEIMER’S PATIENTS, 2002-2050 (MILLIONS) 10
TABLE 2 POPULATION BY SELECTED GEOGRAPHIC REGION, 2011-2050 (MILLIONS) 13
TABLE 3 PERCENT POPULATION OVER 65 BY REGION, 2011 (%) 13
TABLE 4 PEOPLE WITH ALZHEIMER’S DISEASE BY AGE GROUP, 2004-2050 (MILLIONS) 14
TABLE 5 PERCENTAGE OF PEOPLE WITH ALZHEIMER’S, BY AGE BRACKET, 60-94 (%) 14
TABLE 6 GLOBAL DISEASE PREVALENCE: ALZHEIMER’S DISEASE (%) 15
TABLE 7 DIAGNOSTIC TESTS 18
TABLE 8 GLOBAL MARKET FOR ALZHEIMER’S DISEASE BY REGION, THROUGH 2017
($ MILLIONS) 23
TABLE 9 EXISTING TREATMENTS FOR ALZHEIMER’S DISEASE 24
TABLE 10 GLOBAL EXISTING MARKET FOR SYMPTOM-ADDRESSING ALZHEIMER’S
DISEASE BY TYPE, 2010-2017 ($ MILLIONS) 25
TABLE 11 ESTIMATED GLOBAL MARKET FOR ALZHEIMER’S DRUG CLASSES BY
GEOGRAPHICAL REGION (U.S., EUROPE, JAPAN, OTHERS), 2012 ($ MILLIONS) 25
TABLE 12 TYPES OF DRUGS USED TO TREAT ALZHEIMER’S DISEASE 26
TABLE 13 MARKET SHARE OF EXISTING THERAPEUTICS FOR ALZHEIMER’S DISEASE,
2011 (%) 26
TABLE 14 BREAKDOWN OF TREATMENT MARKET BY DISEASE SEVERITY (%) 27
TABLE 15 DEMENTIA RATE BY UNDERLYING DISEASE (%) 27
TABLE 16 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%) 27
TABLE 17 GLOBAL TREATMENT OF ALZHEIMER’S DISEASE, THROUGH 2017 ($
MILLIONS) 28
TABLE 18 GLOBAL POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS,
THROUGH 2017 ($ MILLIONS) 29
TABLE 19 MARKET SHARE OF TOP COMPANIES WORKING IN MEMORY AND
COGNITION (%) 30
TABLE 20 MARKETED TREATMENTS FOR ALZHEIMER’S DISEASE 31
TABLE 21 IMAGING MARKET, 2012 ($ MILLIONS) 33
TABLE 22 BIOMARKERS FOR ALZHEIMER’S DISEASE 37
TABLE 23 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, THROUGH 2017
($ MILLIONS) 38
TABLE 24 SWOT ANALYSIS OF EXISTING ALZHEIMER’S DISEASE MARKET AND
PLAYERS 49
TABLE 25 CHOLINESTERASE INHIBITORS 52
TABLE 26 PRODUCT SIDE EFFECT COMPARISON (%) 53
TABLE 27 VACCINES 54
TABLE 28 ANTI-OXIDANTS 54
TABLE 29 NMDA ANTAGONISTS 54
TABLE 30 NICOTINIC ACETYLCHOLINE ANTAGONISTS 55
TABLE 31 CALCINEURINS 56
TABLE 32 ANTI-EPILEPTIC/GABA MODULATORS 56
TABLE 33 HORMONES 57
TABLE 34 OTC TREATMENTS/NATURAL PRODUCTS 58
TABLE 35 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%) 73
TABLE 36 PERCAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY,
THROUGH 2010 ($ MILLIONS) 76
TABLE 37 DEALS AND PARTNERSHIPS, 2005-2012 84
TABLE 38 DEVELOPMENT PIPELINE OF ALZHEIMER’S DRUGS, BY PHASE 89
TABLE 39 SOME NOT-FOR-PROFIT ORGANIZATIONS AND CONSORTIA IN THE AD
AREA 99
TABLE 40 INVESTMENT IN ALZHEIMER’S DISEASE COMPANIES, 2008-2012 101
TABLE 41 KEY PATENT EXPIRY: ALZHEIMER’S THERAPEUTICS, BY CATEGORY
THERAPEUTICS AND TECHNOLOGIES 107
TABLE 42 MAJOR U.S. PATENT HOLDERS/FILERS IN ALZHEIMER’S 108
TABLE 43 PATENTS ISSUED, 2011-2012 108
TABLE 44 PATENT APPLICATIONS 128

LIST OF FIGURES
SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER’S DISEASE, 2011-2017 ($
MILLIONS) 7
FIGURE 1 U.S. ALZHEIMER’S PATIENTS, 2002-2050 (MILLIONS) 10
FIGURE 2 PEOPLE WITH ALZHEIMER’S DISEASE BY AGE GROUP 2004-2050 14
FIGURE 3 PERCENTAGE OF PEOPLE WITH ALZHEIMER’S, BY AGE BRACKET, 60-94 (%) 14
FIGURE 4 GLOBAL MARKET FOR ALZHEIMER’S DISEASE, BY REGION, 2011-2017 ($
MILLIONS) 23
FIGURE 5 GLOBAL TREATMENT OF ALZHEIMER’S DISEASE, 2010-2017 ($ MILLIONS) 28
FIGURE 6 GLOBAL MEMORY/COGNITION THERAPEUTICS MARKET BY DISEASE AREA,
2011 (%) 29
FIGURE 7 IMAGING MARKET, 2012 ($ MILLIONS) 34
FIGURE 8 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, 2011-2017 ($
MILLIONS) 39
FIGURE 9 PRODUCT SIDE EFFECT COMPARISON (%) 53
FIGURE 10 DEVELOPMENT PIPELINE OF ALZHEIMER’S DRUGS: NUMBER OF
PROGRAMS AT EACH CLINICAL PHASE 95

To order this report:
Diagnostics Industry: Alzheimer`s Disease Therapeutics and Diagnostics: Global Markets

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

RELATED LINKS
http://www.reportlinker.com

FORT WORTH, Texas, May 22, 2013 /PRNewswire/ — A leader in corporate citizenship, AMR Corporation, the parent company of American Airlines and its regional affiliate American Eagle, today released its 2012 Corporate Responsibility Report (CRR). This fifth annual report details the company’s progress and commitment in four key focus areas: customer service and safety, environmental performance, community and employee engagement.

(Logo: http://photos.prnewswire.com/prnh/20130208/DA56847LOGO)

The report provides a transparent summary of key business objectives and features a goals and performance section that measures calendar year 2012 results against established short- and long-term goals. A look ahead at 2013 goals is also presented.

“Corporate responsibility has always been at the core of American’s values, and we remain strongly committed to growing and enhancing these values together with our other business objectives,” said David Campbell , American’s Vice President – Safety and Operations Performance. “Our annual Corporate Responsibility Report is a way to show our people, customers and other stakeholders the positive differences and progress we’re making as the new American.”

Highlights of the report within each focus area include:

Customer Service

• American introduced inflight amenities such as fully lie-flat seats and a walk-up bar for premium customers on the new Boeing 777-300ER aircraft, which launched in January 2013.
• More than 20 network announcements were coordinated, including American’s expanded international service to Latin America, Mexico, Europe and Asia, and new or expanded alliances with 13 airlines were introduced.

Environmental Performance

• AMR was the top-ranked airline in Newsweek‘s 2012 rating of top 500 companies for the third year in a row, ranking second in the Transportation & Logistics sector and 88^th overall.
• Together with Boeing, American successfully piloted the 737-800 ecoDemonstrator program for reduced fuel consumption and noise, and provided a new 737-800 for flight testing.
• Fuel Smart, American’s employee-led fuel conservation program, ended the year with an annual run rate of 147 million gallons in fuel savings, bringing the program’s total savings to 800 million gallons since it began in 2005.

Community Engagement

• American received $733,000 in employee donations through its internal American Giving workplace portal, and its people logged 38,000 volunteer hours for a variety of charitable programs.
• Through the Mass Care Task Force, a joint venture of the Volunteer Center of North Texas, United Way, the American Red Cross and the Salvation Army, 69 American Airlines people were trained as first responders to better assist communities in the event of a natural disaster.

Employee Engagement

• American was again recognized for its diversity and inclusion, receiving a 100 percent Corporate Equality Index rating from the Human Rights Campaign Foundation, and American’s Diversity Advisory Council was named one of the Top 25 Diversity Councils in the nation for the fourth consecutive year.
• At year end, AMR was able to retain a workforce for American Airlines and American Eagle of nearly 81,000 people, while positioning the company more competitively in the airline industry.

As in previous years, the CRR follows the Global Reporting Initiative (GRI) G3 Guidelines, continues to report at the GRI B Application Level, and is formatted as a web-based publication on aa.com.

The full report can be found at http:/www.aa.com/corporateresponsibility.

About American Airlines

American Airlines focuses on providing an exceptional travel experience across the globe, serving more than 260 airports in more than 50 countries and territories. American’s fleet of nearly 900 aircraft fly more than 3,500 daily flights worldwide from hubs in Chicago, Dallas/Fort Worth, Los Angeles, Miami and New York. American flies to nearly 100 international locations including important markets such as London, Madrid, Sao Paulo and Tokyo. With more than 500 new planes scheduled to join the fleet, including continued deliveries of the Boeing 737 family of aircraft and new additions such as the Boeing 777-300ER and the Airbus A320 family of aircraft, American is building toward the youngest and most modern fleet among major U.S. carriers. American’s website, aa.com^®, provides customers with easy access to check and book fares, and personalized news, information and travel offers. American’s AAdvantage^® program, voted Airline Program of the Year at the 2013 Freddie Awards, lets members earn miles for travel and everyday purchases and redeem miles for flights to almost 950 destinations worldwide, as well as flight upgrades, vacation packages, car rentals, hotel stays and other retail products. The airline also offers nearly 40 Admirals Club^® locations worldwide providing comfort, convenience, and an environment with a full range of services making it easy for customers to stay productive without interruption. American is a founding member of the oneworld^® alliance, which brings together some of the best and biggest airlines in the world, including global brands like British Airways, Cathay Pacific, Iberia Airlines, Japan Airlines, LAN and Qantas. Together, its members serve more than 840 destinations served by some 9,000 daily flights to nearly 160 countries and territories. Connect with American on Twitter @AmericanAir or Facebook.com/AmericanAirlines. American Airlines, Inc. and American Eagle Airlines, Inc. are subsidiaries of AMR Corporation. AMR Corporation common stock trades under the symbol “AAMRQ” on the OTCQB marketplace, operated by OTC Markets Group.

 

SOURCE American Airlines

RELATED LINKS
http://www.aa.com

HARRISBURG, Pa., May 22, 2013 /PRNewswire-USNewswire/ – Hikers once again will be picking their pace and path through Pennsylvania‘s bountiful outdoors when Hiking Week 2013 begins on Saturday, May 25, offering participants a variety of organized hikes across the state.

“A wealth of healthy hiking activities is offered to all ages and abilities thanks to the cooperative efforts of the co-sponsoring Keystone Trails Association and our bureaus of state parks and forestry,” Department of Conservation and Natural Resources Secretary Richard Allan said.

“Entering its 12^th year, this event has become increasingly popular as we reach out to the uninitiated and offer a wide variety of highly organized hikes,” Allan said. “The ‘welcome mat’ is out to novices and trail-hardened veterans alike, inviting them to hike in our state parks, forests and municipal greenways in this annual salute to healthy exercise and the serenity of those very special outdoors places.”

The nine-day Hiking Week, offering more than 70 organized hikes, concludes Sunday, June 2, and encompasses National Trails Day on June 1. The co-sponsoring trails association and DCNR have been encouraging suggestions on new hikes that could be added to this year’s schedule at www.ExplorePAtrails.com.

Special events planned by DCNR and the Keystone Trails Association will take place in parks, forests, cities and towns across the state. All of the scheduled hikes have leaders and include a variety of lengths and terrain — from easy strolls along urban greenways to strenuous treks in some of Pennsylvania‘s rugged mountain areas. Special hikes include night hikes; wildflower walks; hikes for people with disabilities; and pet and geology walks.

A goal of more than 100 hikes has been set, with state forests and parks across the state being asked to schedule and oversee activities. For more information, visit http://www.ExplorePAtrails.com/hikingweek.aspx.

Organized in 1956, KTA is an umbrella organization made up of 44 hiking and outdoors organizations in and around Pennsylvania. For more information visit www.KTA-Hike.org.

Media contact: Terry Brady , (717) 772-9101

SOURCE Pennsylvania Department of Conservation and Natural Resources

RELATED LINKS
http://www.dcnr.state.pa.us
http://www.explorepatrails.com/

NEW YORK, May 22, 2013 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Regenerative Medicine Markets
http://www.reportlinker.com/p0236993/Regenerative-Medicine-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement. As such, astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body’s ability to repair itself (or not), or a surgeon’s skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity’s ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms–like the starfish–man-made solutions for tissue repair and organ replacement haven’t come close to nature’s solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by literally regrowing damaged tissue and restoring organ functions through the use of tissue engineering and stem cell therapy. This is the promise of regenerative medicine.

This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures. The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions.

TABLE OF CONTENTS

1. Overview 16
1.1 Statement of Report 16
1.2 Scope of this Report 18
1.3 Methodology 18
1.4 Executive Summary 19

2. Regenerative Medicines: An Overview of Segments 22
2.1 Tissue Engineering 22
2.1.1 Tissue-Engineered Skin 23
2.1.2 Tissue-Engineered Cartilage 23
2.1.3 Tissue-Engineered Bone 24
2.1.4 Tissue-Engineered Peripheral Nerves 25
2.1.5 Tissue-Engineered Cornea 26
2.1.6 Tissue-Engineered Blood Vessels 26
2.1.7 Progress and Promises for Tissue Engineering Industry 27
2.1.7.1 Key Positioning Strategies in Tissue Engineering Industry 27
2.1.7.2 Tissue Engineering Industry Participants 27
2.1.7.3 Tissue Engineering Firms by their Product Applications 28
2.1.7.4 Number of TEFs Focused on Skin, Cartilage, Bone and Urological Products
28
2.1.7.5 Number of Tissue Engineering Firms Focused on Cardiovascular Products 29
2.1.7.6 Number of Tissue Engineering Firms Focused on Neurological Products 30
2.1.7.7 Number of Tissue Engineering Firms Focusing on Pancreas, Liver and
Kidney 30
2.1.7.8 Tissue Engineering Firms Focused on Ophthalmic Products 31
2.1.7.9 Tissue Engineering Firms Involved in Dental Products 31
2.1.7.10 Number of TEFs Involved in Autologous and Allogenic Products 31
2.1.7.11 Geographic Distribution of Tissue Engineering Firms in Major Markets 31
2.2 Cell Therapy 32
2.2.1 Progress in Cell Therapy Product Research 34
2.2.2 Commercially Available Cell Therapy Products 35
2.2.3 Major Cell Therapy Companies 36
2.2.4 Locations of Cell Therapy Companies 38
2.2.5 Disease Focus by Cell Therapy 39
2.2.6 Cell Therapy Products and Companies 39
2.2.6.1 Autologous Structural Products for Cartilage, Skin, Bone, etc. 41
2.2.7 Potential Patients for Cell Therapy in the U.S. 41
2.2.8 Number of Patients Treated Between 1988 and 2010 by Cell Therapy 41
2.2.9 Cell Therapy Pipeline 42
2.2.10 Cell Therapy Clinical Trials by Indication 43
2.2.10.1 Major Cell Therapy Clinical Trials for Diabetes 43
2.2.10.2 Progress in Clinical Trials for Diabetes 44
2.2.10.3 Estimated Completion Dates for Cell Therapy Clinical Trials in Diabetes
44
2.2.11 Major Four Targeted Disease Conditions for Clinical Trials 45
2.2.12 Commercial Success of Cell Therapies in Europe 46
2.2.13 Deals in Cell Therapy, 2007-2011 49
2.2.14 Commercial-Stage Cell Therapy Companies and Products 50
2.2.15 Cell Therapy Clinical Trials in the U.K. 51
2.2.15.1 Clinical Trials Involving Allogeneic vs. Autologous Products in the
U.K. 52
2.2.15.2 Cell Types Involved in the U.K. Clinical Trials 53
2.2.15.3 U.K. Cell Therapy Clinical Trials by Indication 53
2.3 Cell Culture Products 54
2.3.1 Market for Reagents Used in Cell Culture 55
2.3.2 Cell Culture Media 56
2.3.3 Market for Sera Used in Cell Culture 57
2.3.3.1 Suppliers of Culture Media and Reagents 58
2.3.3.2 In Vitro Test Kits 59
2.3.3.3 Suppliers of Cells and Tissues 59
2.3.3.4 Equipment for Stem Cell Research 60
2.3.3.5 Computer Software for Stem Cell Research 62
2.4 Scaffolding Biomaterials 63
2.5 Growth Factors 64

3. Regenerative Medicine: The Next Evolution of Medical Treatment 66
3.1 Scope of this Chapter 66
3.2 Need for Regenerative Medicine 66
3.3 Current State of Regenerative Medicines 66
3.4 Future of Regenerative Medicine 67
3.4.1 Number of Products in Pipeline 68
3.5 Projected Timeline for Regenerative Medicine 72
3.6 Selected Regenerative Medicine Products in the Market 72
3.6.1 Medtronic’s Infuse Bone Graft and LT-Cage Device 73
3.6.2 Genzyme’s Corticel 73
3.6.3 OP-1 from Stryker 75
3.6.4 Osteocel from Osyris/Nuvasive 75
3.6.5 Spinal Implants from RTI Biologics 76
3.6.6 Apligraf from Organogenesis 76
3.6.7 Dermograft from Advanced BioHealing 76
3.6.8 Integra’s Bilayer Matrix for Wound Dressing 77
3.6.9 Alloderm from LifeCell 77
3.6.10 Celution from Cytori Therapeutics 78
3.6.11 Other Products of Importance in Regenerative Medicine 78
3.6.12 Tissue-Engineered Wound Healing Products 78
3.6.12.1 Oasis 79
3.6.12.2 Permacol 79
3.6.12.3 EZ-Derm 79
3.6.12.4 Matriderm 80
3.6.12.5 TransCyte 80
3.6.12.6 ICX-SKN 80
3.6.12.7 OrCel 81
3.6.12.8 Epicel 81
3.6.12.9 Myskin 82
3.6.12.10 VCT01 82
3.6.13 ICX-TRC—Hair Regeneration Therapy 82
3.6.14 Cartilage Regeneration 82
3.6.14.1 Novocart 82
3.6.14.2 BioSeed-C 83
3.6.14.3 BioSeed—Oral Bone 83
3.6.14.4 Chondrotissue 83
3.6.14.5 co.don Chondrotransplant 83
3.6.14.6 co.don Chondrotransplant DISC 83
3.6.14.7 co.don Chondrosphere 83
3.6.14.8 co.don Osteotransplant DENT 84
3.6.14.9 MACI Implant 84
3.6.14.10 Cartilink-3 84
3.6.14.11 Accell Evo3 Demineralized Bone Matrix 84
3.6.14.12 OsSatura BCP 84
3.6.15 Mozobil 84
3.7 Clinical Milestones in RM Sector, 2011-2012 84
3.7.1 GINTUIT (March 2012) 84
3.7.2 Ixmyelocel-T (February 2012) 84
3.7.3 Autologous CD34+ Stem Cells (February 2012) 85
3.7.4 HuCNS-SC (February 2012) 85
3.7.5 DeNovo ET (February 2012) 85
3.7.6 Retinal Pigment Epithelium Cells (January 2012) 85
3.7.7 AMR-001 (January 2012) 85
3.7.8 Avance Nerve Graft (January 2012) 85
3.7.9 Adipose-Derived Stem Cells to Treat Myocardial Ischemia (January 2012) 86
3.7.10 T-Cells Resistant to HIV (January 2012) 86
3.7.11 Tissue-Engineered Windpipe (November 2011) 86
3.7.12 Revascor (November 2011) 86
3.7.13 ReN001 Stem Cell Therapy (September 2011) 86
3.7.14 HP802-247 Allogeneic Cell Suspension for Leg Ulcers (August 2011) 86
3.7.15 ALD-301 for Critical Limb Ischemia (May 2011) 86
3.7.16 JVS-100 for Heart Failure (April 2011) 87
3.7.17 MultiStem for Ulcerative Colitis (March 2011) 87
3.7.18 HuCNS-SC Human Neural Stem Cells (March 2011) 87
3.8 Accelerated Pace of Deals in RM Sector 87
3.8.1 Acquisitions and Partnerships 87
3.8.1.1 Shire’s Acquisition of Advanced BioHealing, Inc. (May 2011) 87
3.8.1.2 Terumo Americas Holding’s Acquisition of Harvest Technologies (April
2011) 87
3.8.1.3 Sanofi’s Acquisition of Genzyme Corporation (February 2011) 87
3.8.1.4 NeoStem’s Acquisition of Progenitor Cell Therapy, LLC (January 2011) 87
3.8.1.5 Strategic Alliance between Mesoblast and Cephalon, Inc. (December 2011)
88
3.8.2 Notable Financings 88
3.8.2.1 Financing to AlloCure, Inc. (April 2012) 88
3.8.2.2 Financing to Promethera Biosciences (March 2012) 88
3.8.2.3 Financing to In Vivo Therapeutics Holdings Corp. (February 2012) 88
3.8.2.4 Financing to Organovo (March 2012) 88
3.8.2.5 Financing to Cytomedix, Inc. (February 2012) 88
3.8.2.6 Financing to Fate Therapeutics, Inc. (May 2011) 88
3.8.2.7 Financing to Cellular Dynamics International, Inc. (April 2011) 89
3.8.2.8 Financing to Cytori Therapeutics (December 2010) 89
3.8.2.9 Overview of Capital Formation in RM Industry 89

4. Recent Advances in Regenerative Medicine and Stem Cell Research 90
4.1 Bioengineered Autologous Vein 90
4.2 Stem Cell Treatment for Spinal Cord Injury 90
4.3 Repairing Damaged Retina 90
4.4 A Possible Cure for Deafness 91
4.5 Clinical Trials for Stem Cell Therapies for CNS Disorders by StemCells, Inc.
91
4.6 First Clinical Use of Bioengineered Vascular Graft Made from Autologous Stem
Cells 92
4.6.1 Recent Developments in Stem Cell Therapy in Cardiology 92
4.6.2 Recent Developments in Acute MI 92
4.6.3 Chronic Ischemic Cardiomyopathy and Heart Failure 94
4.6.4 Stem Cells and Neurodegenerative Diseases 95
4.7 Disease Modeling: The Use of Inducible Cells 96
4.7.1 Modeling Disease with iPS Cells 96
4.7.2 Modeling Disease with Direct Neuronal Conversion 97
4.8 Stem Cell Transplants 97
4.8.1 Recent Developments in Ophthalmologic Stem Cell Transplantation Therapies
98
4.8.2 Stem Cell Types for Eye Disease Clinical Trials 98
4.8.2.1 Pluripotent Stem Cells 99
4.8.2.2 Neural Stem Cells 99
4.8.2.3 RPE Stem Cells 99
4.8.2.4 Limbal Stem Cells 99
4.8.2.5 Umbilical Cord Stem Cells 99
4.8.2.6 Bone Marrow Stem Cells 99
4.8.2.7 Pluripotent Stem Cells for Retinal and RPE Degeneration 99
4.8.2.8 Patch of hESC-Derived RPE Monolayer 100
4.8.2.9 Patient-Derived RPE 100
4.8.2.10 NSCs for AMD 100
4.8.2.11 UCSCs for RP and AMD 101
4.8.2.12 Bone Marrow Stem Cells for Photoreceptor Diseases 101
4.8.2.13 Corneal Repair 101
4.8.2.14 Bioengineered Eye Tissues 101
4.9 Regenerative Strategies in the Treatment of Diabetes 101
4.9.1 Cell-Based Therapy for Diabetes 102
4.9.2 Embryonic Stem Cells and Induced Pluripotent Cells 102

5. Stem Cell Industry Highlights, 2012 104
5.1 Business Development 104
5.2 Clinical Trials 104
5.3 Market Authorization 104
5.4 Regulations 105
5.5 Capital Market and Finances 105
5.6 Investments in Xeno-Cell Therapy 105
5.7 Collaborations in Stem Cell Science 106
5.7.1 California Institute for Regenerative Medicine (CIRM) 106
5.7.2 The International Translational Regenerative Medicine Center 111

6. Regenerative Medicines: A Brief Update from Selected Countries 112
6.1 U.S. 112
6.1.1 Key Institutions 112
6.1.1.1 California Institute for Regenerative Medicine 112
6.1.1.2 The New York Stem Cell Foundation 112
6.1.1.3 NIH Center for Regenerative Medicine 112
6.1.2 Innovative Company 112
6.1.2.1 Aastrom Biosciences 112
6.2 Canada 113
6.2.1 Key Institutions 113
6.2.1.1 Institute of Biomaterials & Biomedical Engineering, University of
Toronto 113
6.2.1.2 Terry Fox Research Institute 113
6.2.1.3 Institute for Research in Immunology and Cancer, University of Montreal
113
6.2.2 Innovative Companies 113
6.2.2.1 Northern Therapeutics 113
6.2.2.2 Octane Biotech 113
6.3 U.K. 113
6.3.1 Key Institutions 114
6.3.1.1 Loughborough University 114
6.3.1.2 U.K. Stem Cell Foundation 114
6.3.1.3 University College, London 114
6.3.2 Innovative Companies 114
6.3.2.1 Intercytex 114
6.3.2.2 Azellon Cell Therapeutics 115
6.3.2.3 Cell Medica 115
6.4 Sweden 115
6.4.1 Key Institutions 115
6.4.1.1 Karolinska Institutet 115
6.4.1.2 The University of Lund 115
6.4.2 Innovative Companies 116
6.4.2.1 Vitrolife 116
6.4.2.2 Cellartis 116
6.4.2.3 Biolamina 116
6.5 Brazil 116
6.5.1 Key Institutions 116
6.5.1.1 Universidade de SaoPaulo 116
6.5.1.2 Fiocruz and Hospital Sao Rafael 116
6.5.1.3 Universidade Federal do Rio de Janeiro 117
6.5.1.4 Pontificia Universidade Catolica do Parana 117
6.5.2 Innovative Company 117
6.5.2.1 Excellion & CellPraxys 117

7. Market Analysis for Regenerative Medicine Sector 118
7.1 Scope of this Chapter 118
7.2 Opportunities for RM Products 118
7.3 Commercial RM Products 119
7.3.1 Leading Commercial Cell Therapy Products 119
7.3.2 FDA Approved Cell-Based Products 120
7.3.3 Growth Spurt by Regenerative Medicine (RM) 121
7.4 Global Market for Tissue-Engineered Products 122
7.4.1 Tissue Engineering and Stem Cell Industry 124
7.5 Market for Stem Cell Therapy in Cardiology 124
7.6 Market for RM Products in Orthopedics 126
7.6.1 No Strong Alternatives for Medtronic’s INFUSE 127
7.6.2 Demineralized Bone Matrix (DBM) 128
7.6.3 The Unproven Stem Cells in Orthopedics 128
7.6.4 Future of Bone Replacement Market 129
7.7 Global RM Market for Neurology Products 130
7.8 Market for RM Dental Products 131
7.9 Market for RM Cancer Products 132
7.10 RM Market for Urology Products 133
7.11 Global Market for Skin Products 134
7.12 Overall Global RM Market 135
7.13 U.S. Market for Tissue-Engineered Skin 136
7.14 U.S. RM Market for Orthopedic/Spine Products 138
7.15 U.S. RM Market for Nerve Repair Products 140
7.16 U.S. RM Market for Cardiovascular and Stroke Products 141
7.17 U.S. Market for Anti-Inflammatory RM Products 142
7.18 U.S. Market for RM Products in Diabetes 142
7.19 Overall U.S. Regenerative Medicine Market 143
7.19.1 U.S. RM Market by Segment 144

8. Stem Cell Industry 146
8.1 Global Market for Stem cells 147
8.2 Stem Cell Use in the U.S. 148
8.2.1 Autologous Stem Cell Use in the U.S. 148
8.2.2 U.S. Stem Cell Market Overview 149
8.2.2.1 Potential U.S. Population for Cell-Based Therapies 150
8.2.3 U.S. Market for Stem cells 151
8.3 European Market for Stem Cells 153
8.3.1 Autologous and Allogeneic Cell Therapy Companies in Europe 154
8.4 Asia-Pacific Market for Stem Cells 155
8.5 Autologous Cell Therapy 156
8.5.1 Commercially Available Autologous Treatments 156
8.5.1.1 Autologous Cell Therapy for Alzheimer’s disease 157
8.5.1.2 Autologous Cell Therapy for Multiple Sclerosis 157
8.5.1.3 Autologous Cell Therapy for Wound Healing 157
8.5.1.4 Autologous Therapy for Cosmetic Surgery 158

9. Business Models and Requirements for a Successful Regenerative Medicine
Industry 159
9.1 Scope of this Chapter 159
9.2 Business Models in Regenerative Medicine 159
9.2.1 Current Model for Autologous Cell Therapies 160
9.2.2 Current Models for Allogeneic Cell Therapies 161
9.3 Key Factors for Successful Business Models for Cell Therapies 163
9.4 Requirements for Commercial Manufacturing of Cell Therapy Products 163
9.4.1 Elements of Commercial Manufacturing 163
9.4.1.1 Regulatory Requirements 163
9.4.1.2 Manufacturing Process Scale 164
9.4.1.3 In-House Manufacturing 164
9.4.1.4 Contract Manufacturing: Commercial and Academic 165

10. Company Profiles 167
10.1. Aastrom Biosciences, Inc. 167
10.1.1 Aastrom’s Cellular Therapy and Ixmyelocel-T 167
10.1.1.1 Advantages of Patient’s Bone Marrow and Ixmyelocel-T 167
10.1.2 Aastrom’s Clinical Trials 168
10.1.2.1 REVIVE-CLI 168
10.1.2.2 RESTORE-CLI 168
10.2 Advanced Cell Technology, Inc. (ACT) 168
10.2.1 ACT’s Human ES Cell Programs 169
10.2.2 ACT’s Human Embryonic Stem Cell Technologies 169
10.2.3 ACT’s Cell Therapy Research Program 170
10.2.3.1 Retinal Pigment Epithelium Program 170
10.2.3.2 Hemangioblast Program 170
10.2.3.3 Adult Stem Cell Program 170
10.2.4 ACT’s Intellectual Property 171
10.3 AlloCure, Inc. 172
10.3.1 AlloCure’s Technology 172
10.3.2 AlloCure’s Clinical Trials 173
10.3.2.1 Acute Kidney Injury 173
10.3.2.2 Epidemiological Study of AKI 173
10.3.2.3 Phase I Clinical Trial in AKI 174
10.3.2.4 Phase II Clinical Trial in AKI 174
10.4 Altrika Ltd. 174
10.4.1 Myskin 174
10.4.2 Cryoskin 174
10.5 American Type Culture Collection, Inc. (ATCC) 175
10.5.1 ATCC’s Cell Lines and Hybridomas 175
10.5.2 ATCC’s Media, Sera and Reagents 175
10.5.3 MTT Cell Proliferation Assay 175
10.5.4 XTT Cell Proliferation Assay Kit 175
10.5.5 Universal Mycoplasma Detection Kit 176
10.5.6 DNA and RNA 176
10.5.7 STR Profile Database 176
10.5.8 hTERT Immortalized Cell Lines 176
10.5.9 Embryonic Stem Cell Products 177
10.5.10 Bacteria and Phages 177
10.5.11 Fungi and Yeast 177
10.5.12 Protozoa and Algae 177
10.5.13 Viruses and Related Reagents 177
10.5.14 Microbial DNA and RNA 178
10.5.15 ATCC’s Tissue Biology Products 178
10.6 Avita Medical Limited 178
10.6.1 ReCell 178
10.7 Amorcyte, LLC 178
10.7.1 AMR-001 179
10.8 Ars Arthro AS 179
10.8.1 CaReS 179
10.8.2 Fibrocell 179
10.8.3 Fibroplus 179
10.9 Axiogenesis AG 179
10.9.1 Human iPS Cell-Derived Cardiomyocytes 180
10.9.2 Murine Cardiomyocytes ES 180
10.9.3 Murine Cardiomyocytes iPS 180
10.9.4 Murine Endothelial Cells 180
10.9.5 Murine Smooth Muscle Cells 181
10.10 AxoGen, Inc. 181
10.10.1 Avance Nerve Graft 181
10.10.2 AxoGuard Nerve Protector 182
10.10.3 AxoGuard Nerve Connector 182
10.11 Bellicum Pharmaceuticals, Inc. 182
10.11.1 Bellicum’s Technology 183
10.11.2 Bellicum’s Pipeline 184
10.12 BetaStem Therapeutics, Inc. 184
10.12.1 BetaStem’s Technology 185
10.13 Bioheart, Inc. 185
10.13.1 MyoCell 185
10.13.2 MyoCell SDF-1 186
10.13.3 MyoCath 186
10.13.4 LipiCell 186
10.14 Biomet, Inc. 187
10.14.1 Endobon Xenograft Granules 187
10.14.2 RegenerOss Allograft 188
10.14.3 Ground Cancellous Bone 188
10.15 BioMimetic Therapeutics, Inc. 189
10.15.1 Augment Bone Graft 190
10.15.2 Augmatrix Biocomposite Bone Graft 190
10.16 BioTissue Technologies AG 191
10.16.1 BioSeed-C 191
10.16.2 Chondrotissue 191
10.16.3 BioSeed-Oral Bone 192
10.17 Biovest International, Inc. 192
10.17.1 Autovaxid 192
10.17.2 Xcellerator 193
10.17.3 Maximizer 193
10.17.4 Minimax 193
10.18 BrainStorm Cell Therapeutics, Inc. 193
10.18.1 NurOwn 194
10.19 California Stem Cell, Inc. 194
10.19.1 Clinical Pipeline 194
10.19.1.1 MotorGraft 194
10.19.1.2 Cancer Stem Cell 194
10.19.2 Cell Products 195
10.19.2.1 MotorPlate and MotorVial 195
10.19.2.2 NeuroPlate and NeuroVial 195
10.19.2.3 OPCVial 195
10.19.2.4 HepatoPlate 196
10.19.3 Cell Culture Products 196
10.19.3.1 StemBlast 196
10.19.3.2 MotorBlast 196
10.19.3.3 NeuroBlast 197
10.19.3.4 OPC Media 197
10.19.3.5 Cellular Transplant Solution 197
10.20 Cardio3 Biosciences SA 197
10.20.1 Products Pipeline 198
10.20.1.1 C3BS-CQR-1 (C-Cure) 198
10.20.1.2 Positive Phase II Results for C-Cure 198
10.20.1.3 C3BS-CQR-1 (Protein) 198
10.20.1.4 C-CATHez (Medical Device) 198
10.21 Cellartis AB (Cellectis) 199
10.21.1 iPS Engineering Hub 199
10.21.2 Hepatocytes hiPS-HEP 199
10.21.3 Cardiomyocyte Clusters hES-CMC 200
10.21.4 Stem Cell Culture System DEF-CS 200
10.22 CellSeed, Inc. 200
10.22.1 Epithelial Cell Sheet for Corneal Regeneration 200
10.22.2 Regenerated Cardiac Patch 201
10.22.3 Epithelial Cell Sheet for Esophageal Regeneration 201
10.22.4 Cell Sheet for Periodontal Regeneration 201
10.22.5 Regenerated Cartilage Sheet 201
10.23 Cellular Dynamics International, Inc. 201
10.23.1 iCell Cardiomyocytes 202
10.23.2 iCell Endometrial Cells 202
10.23.3 iCell Hepatocytes 202
10.23.4 iCell Neurons 202
10.23.5 MyCell Products 202
10.24 Chromocell Corporation 203
10.24.1 Chromovert Technology 203
10.24.2 Chromovert Applications 203
10.24.2.1 Pain Relief 203
10.24.2.2 Anxiety Treatments 204
10.24.2.3 Respiratory Disorders 204
10.25 Cognate Bioservices, Inc. 204
10.25.1 Process Development 204
10.25.2 Regulatory Services 204
10.25.3 Assay Development 205
10.25.4 Preclinical Services 205
10.25.5 Stem Cell Services 206
10.26 Cook Biotech, Inc. 206
10.26.1 Cook’s Technology 206
10.26.2 Biodesign Dural Graft 207
10.26.3 Dynamatrix Extracellular Membrane 207
10.26.4 tarSys 207
10.26.5 Oasis Wound Matrix 207
10.26.6 Biodesign Staple Line Reinforcement 208
10.26.7 Biodesign Hiatal Hernia Graft 208
10.26.8 CorMatrix ECM 208
10.26.9 ECM for Cardiac Tissue Repair 209
10.26.10 Biodesign Incision Graft 209
10.26.11 Biodesign Inguinal Hernia Graft 209
10.26.12 Biodesign Parastomal Reinforcement Graft 210
10.26.13 Biodesign Umbilical Hernia Graft 210
10.26.14 Biodesign Anterior Pelvic Floor Graft 210
10.26.15 Biodesign Fistula Plug 211
10.26.16 LIFT with Biodesign 211
10.26.17 Biodesign Posterior Pelvic Floor Graft 211
10.26.18 Biodesign Peyronie’s Repair Graft 212
10.26.19 Biodesign Tension-Free Urethral Sling 212
10.27 Cytomedix, Inc. 212
10.27.1 Cytomedix’s AutoloGel System 213
10.27.1.1 The Working of AutoloGel System 213
10.27.1.2 Balancing Effect of AutoloGel System 213
10.27.1.3 Formulation of AutoloGel System 214
10.27.2 Cytomedix’s Angel PRP 214
10.28 Cytonet, LLC 215
10.28.1 Cytonet’s Liver Cell Therapy 215
10.28.2 SELICA III Clinical Trial 215
10.29 Cytori Therapeutics, Inc. 215
10.29.1 Cytori’s Commercial Activities and Markets 215
10.29.2 Cytori’s Pipeline 216
10.29.2.1 Celution System for Cardiovascular Disease 216
10.29.2.2 Other Applications of Celution System 217
10.29.2.3 PureGraft 217
10.29.2.4 StemSource 217
10.30 DanDrit Biotech A/S 218
10.30.1 Dendritic Cell 218
10.30.1.2 Colorectal Cancer Trial Phase II in Singapore 219
10.30.1.3 Non-Small-Cell Lung Cancer, Phase II 219
10.31 Fibrocell Science, Inc. 219
10.31.1 Fibrocell’s Technology 220
10.31.2 Pipeline 220
10.32 Forticell Bioscience, Inc. 220
10.32.1 OrCel 220
10.33 Gamida Cell Ltd. 221
10.33.1 Gamida’s Technology 221
10.33.1.1 Copper Chelator Based Technology 221
10.33.1.2 NAM Based Technology 221
10.33.1.3 StemEx 222
10.33.1.4 NiCord 222
10.33.1.5 CordBridge 223
10.33.1.6 NK Cell Product 223
10.34 Harvest Technologies Corporation 223
10.34.1 Smart PReP2 APC+ 223
10.34.2 SmartPReP 2 BMAC 224
10.35 Histogenics Corporation 224
10.35.1 NeoCart 224
10.35.2 VeriCart 226
10.36 Humacyte, Inc. 226
10.36.1 Humacyte Grafts 226
10.37 Integra Lifesciences Holdings Corporation 227
10.37.1 Integra’s Products Overview 227
10.37.2 Integra’s Orthopedics Product Portfolio 227
10.37.3 Integra’s Extremity Reconstruction Product Portfolio 227
10.37.3.1 Skin and Wound 227
10.37.3.2 Bone and Joint Fixation Devices and Instruments 228
10.37.3.3 Lower Extremity Products 228
10.37.3.4 Upper Extremity Products 228
10.37.3.5 Bone Graft Substitutes for Extremity Reconstruction 228
10.37.3.6 Nerve and Tendon 228
10.37.4 Integra’s Spine Product Portfolio 228
10.37.4.1 Integrated Interbody Fusion Devices 229
10.37.4.2 Minimally Invasive Solutions 229
10.37.4.3 Deformity Correction 229
10.37.4.4 Orthobiologics 229
10.37.4.5 Integra’s Research and Development in Regenerative Medicine 229
10.38 Intercytex Ltd. 229
10.38.1 VAVELTA 230
10.38.2 Epidermolysis Bullosa 230
10.38.3 Scar Contractures 231
10.38.4 Acne Scarring 231
10.38.5 International Stem Cell Corporation 231
10.38.6 Therapeutic Programs 232
10.39 iPierian, Inc. 232
10.39.1 Technology 233
10.39.2 Product Development 233
10.40 Japan Tissue Engineering Co., Ltd. 233
10.40.1 Autologous Cultured Epidermis 233
10.40.2 Autologous Cultured Cartilage 234
10.40.3 Autologous Cultured Corneal Epithelium 235
10.41 Kensey Nash Corporation 235
10.41.1 Medeor Matrix 236
10.41.2 Meso BioMatrix Scaffold 236
10.41.3 Epi-Guide Bioresorbable Barrier Matrix 236
10.41.4 OsseoFit Porous Tissue Matrix 237
10.41.5 Vitoss Scaffold Foam Products 237
10.42 Kiadis Pharma B.V. 237
10.42.1 Kiadis’ Pipeline 238
10.42.1.1 ATIR 238
10.42.1.2 Reviroc 239
10.42.1.3 Rhitol 240
10.43 Living Cell Technologies Limited (LCT) 240
10.43.1 Diabecell 240
10.43.2 Ntcell 240
10.44 Life Cell Corporation 241
10.44.1 AlloDerm 241
10.44.2 Cymetra Micronized AlloDerm Tissue 241
10.44.3 Strattice Reconstructive Tissue Matrix 242
10.44.4 SPY Elite System 242
10.45 MaxCyte, Inc. 243
10.45.1 MaxCytes Technology Platform 243
10.45.2 Drug Discovery Applications 243
10.45.2.1 GPCRs 243
10.45.2.2 Ion Channels 243
10.45.3 Antibody Production 244
10.45.4 General Protein Production 244
10.45.5 Viral Vector and VLP Production 244
10.45.6 Insect Cell Transfection 244
10.45.7 Cell Therapy 244
10.45.7.1 Dendritic Cell Vaccines 244
10.45.7.2 Regenerative Medicine 245
10.45.7.3 Chimeric Antigen Receptor (CAR) Immunotherapy 245
10.46 MediStem, Inc. 245
10.46.1 Intellectual Property 246
10.46.1.1 Method for Expansion of Stem Cells 246
10.46.1.2 Compositions of Placentally-Derived Stem Cells for the Treatment of
Cancer 246
10.46.1.3 Transcatheter Tumor Immunoembolization 246
10.46.1.4 Stem Cell Therapy for Cardiac Valvular Dysfunction 246
10.46.1.5 Treatment of Erectile Dysfunction by Stem Cell Therapy 246
10.46.1.6 Allogeneic Stem Cell Transplants in Non-Conditioned Recipients 246
10.46.1.7 Stem Cell Mediated Treg Activation for Therapeutic Immune Modulation
247
10.46.1.8 Cellular Therapy for Lower Back Pain 247
10.46.1.9 Compositions and Methods of Stem Cell Therapy for Autism 247
10.46.1.10 Stem Cell Therapy for Weight Loss 247
10.46.1.11 Menstrual Blood Cellular Populations, Isolation, and Use Thereof 247
10.46.1.12 Endometrial Derived Reparative/Regenerative Cells 247
10.46.1.13 Treatment of Insulin Resistance and Diabetes 248
10.46.1.14 Combination Treatment of Cardiovascular Disease 248
10.46.1.15 Stem Cell Therapy for Autism 248
10.46.2 Product Pipeline 248
10.46.2.1 Endometrial Regenerative Cell Platform 248
10.46.2.2 Angiostem Platform 248
10.46.2.3 Tolerostem Platform 248
10.47 Mesoblast Ltd. 249
10.47.1 Revascor 249
10.47.2 MPCs for Diabetics 249
10.47.3 Bone Marrow Derived Allogeneic MPCs 249
10.47.4 Macular Degeneration 250
10.47.5 Diabetic Macular Edema 250
10.47.6 Intervertebral Disc Repair Product 250
10.47.7 Lumbar and Cervical Spinal Fusion Product 251
10.47.8 Fracture Repair Product 251
10.47.9 Arthritis Product 251
10.48 MolMed S.p.A. 252
10.48.1 MolMed’s Technological Platforms 253
10.49 NanoCor Therapeutics, Inc. 253
10.49.1 Carfostin 253
10.50 Neuralstem, Inc. 253
10.50.1 Neuralstem’s Technology Platforms: Stem Cells 253
10.50.2 Pharmaceutical Compounds 254
10.50.3 Neuralstem’s Clinical Trials for Stem Cells 255
10.50.4 Clinical Trials for Neuralstem’s Pharmaceutical Compound 255
10.51 NeuroNova AB 255
10.51.1 Neurogenesis Qualifier 255
10.51.2 NeuroNova’s Projects 256
10.52 Olympus Terumo Biomaterials Corp. 256
10.52.1 OSferion60 256
10.52.2 Terudermis 256
10.52.3 OSferion 258
10.52.4 Teruplug 258
10.52.5 Bone Cream 258
10.53 NewLink Genetics Corporation 258
10.54 OncoMed Pharmaceuticals, Inc. 259
10.54.1 OncoMed’s Research on Cancer Stem Cells 259
10.54.2 OncoMed’s Platform 260
10.54.3 OncoMed’s Development Pipeline 260
10.55 Opexa Therapeutics, Inc. 261
10.55.1 T-Cell Platform 261
10.56 Organogenesis, Inc. 261
10.56.1 Apligraf 261
10.56.2 Gintuit 262
10.57 Orthovita, Inc. 262
10.57.1 Vitoss 263
10.58 Osiris Therapeutics, Inc. 263
10.58.1 Osiris’ Technologies 264
10.58.1.1 Stem Cell Source 264
10.58.1.2 Manufacturing Process 264
10.59 Osteotech, Inc. 265
10.59.1 MagniFuse 265
10.59.2 Plexur P 265
10.59.3 Plexur M 266
10.59.4 FacetLinx Fusion Technology 266
10.59.5 Grafton 266
10.59.6 Xpanse Bone Inserts 267
10.59.7 GraftCage TLX and GraftCage ACX 267
10.60 Pervasis Therapeutics, Inc. 267
10.61 Pluristem Therapeutics, Inc. 268
10.62 Proneuron Biotechnologies, Inc. 269
10.62.1 Spinal Cord Technology 269
10.63 RegeneRx 270
10.63.1 Tß4 Peptide Research 270
10.64 ReNeuron Group PLC 271
10.64.1 ReN001 271
10.64.2 ReN009 271
10.64.3 ReNcell VM and ReNcell CX 272
10.65 Revivicor, Inc. 272
10.65.1 Xenotransplantation Technology 272
10.66 SanBio, Inc. 273
10.66.1 SanBio’s Product Pipeline 273
10.66.1.1 SB623 273
10.66.1.2 SB618 273
10.66.1.3 SB308 273
10.67 Saneron CCEL Therapeutics, Inc. 274
10.67.1 U-Cord Cell Program 274
10.67.2 Sert-Cell Program 274
10.68 Sangamo Biosciences, Inc. 274
10.68.1 SB-728 274
10.68.2 SB-313 275
10.68.3 Hemophilia 275
10.69 Stem Cell Authority Ltd. 275
10.69.1 MIRACHYMAL Stem Cells 275
10.70 StemCells, Inc. 275
10.70.1 StemCells’ Research Collaborations 276
10.70.1.1 Stanford University and Stanford School of Medicine 276
10.70.1.2 UC Irvine 276
10.70.1.3 OHSU Casey Eye Institute 276
10.70.1.4 McLaughlin Research Institute 276
10.70.2 StemCells’ Therapeutic Programs 276
10.70.3 Cells and Cell Lines 277
10.70.4 Cell Culture Products 277
10.70.5 Antibody Detection Reagents 277
10.70.6 Purified Whole Stem Cell Lysates 277
10.71 Stemline Therapeutics, Inc. 278
10.71.1 Cancer Stem Cells 279
10.71.2 Stemline Therapeutics’ Platform 279
10.72 Stratetech Corporation 279
10.72.1 Stratatech’s Core Technology 279
10.73 Synthecon, Inc. 280
10.73.1 Rotary Cell Culture Systems 280
10.73.2 Biofelt (Bioabsorbable Scaffold) 281
10.73.3 Biomerix 3D Scaffolds 281
10.73.4 RollerCell 40 281
10.74 Tengion, Inc. 282
10.74.1 Tengion’s Scientific Platform 282
10.74.2 Tengion’s Pipeline 283
10.75 TiGenics NV 283
10.75.1 ChondroCelect 284
10.75.2 CX601 284
10.75.3 Cx611 285
10.75.4 Cx621 285
10.76 Tissue Genesis, Inc. 285
10.76.1 Clinical Therapies from Tissue Genesis 285
10.76.1.1 Icellator 286
10.76.1.2 Adipase 286
10.77 Thermogenesis Corp. 286
10.77.1 AXP System 286
10.77.2 MXP System 287
10.77.3 Manual Systems 287
10.77.4 Res-Q 60 BMC System 288
10.77.5 BioArchive System 288
10.78 ViaCyte, Inc. 288
10.78.1 Technology Overview 289
10.79 Vistagen Therapeutics, Inc. 289
10.79.1 Vistagen’s Technology 289
10.79.2 CardioSafe 3D 290
10.79.3 LiverSafe 3D 290
10.80 Zen-Bio, Inc. 290

Appendix 1: Allogeneic vs. Autologous Stem Cell Therapy 292
Appendix 1.1: Manufacturing Process 292
Appendix 1.2: Cost Differential 293
Appendix 1.3: Donor Screening and Testing 294
Appendix 1.4: Release Testing 294
Appendix 1.5: Overall Analysis 294

INDEX OF FIGURES

Figure 2.1: Geographic Distribution of Tissue Engineering Firms in Major Markets
32
Figure 2.2: The Potential Uses of Embryonic Stem Cells 33
Figure 2.3: Progress of Cell Therapy Product Research, 2012 34
Figure 2.4: Commercially Available Cell Therapy Products, 2012 35
Figure 2.5: Disease Focus by Regenerative Medicine 39
Figure 2.6: Estimated Completion Dates for Stem Cell Based Clinical Trials
Targeting Type 1 Diabetes,
2009-2015 45
Figure 2.7: Number of Clinical Trials by Targeted Condition, 2005-2011 45
Figure 2.8: Concentration of European Cell Therapy Firms, 2012 46
Figure 2.9: European Stem Cell Platforms by Cell Source 47
Figure 2.10: Autologous vs. Allogeneic Stem Cell Therapy Firms in Europe, 2012
48
Figure 2.11: Autologous and Allogeneic Somatic Cell Therapy Firms in Europe,
2012 48
Figure 2.12: Sponsors of Cell Therapy Clinical Trials in the U.K., 2012 52
Figure 2.13: Clinical Trials Involving Allogeneic vs. Autologous Cell Therapy
Products in the U.K., 2012 52
Figure 2.14: Cell Types Involved in the U.K. Cell Therapy Clinical Trials, 2012
53
Figure 2.15: U.K. Cell Therapy Clinical Trials by Indication, 2012 54
Figure 2.16: Cell Culture Products Market by Segment, 2012 55
Figure 2.17: Market for Reagents Used in Cell Culture, 2012-2019 56
Figure 2.18: Market for Media Used in Cell Culture, 2012-2019 57
Figure 2.19: Market for Serum Used in Cell Culture, 2012-2019 58
Figure 5.1: CIRM’s Grants for Disease Types by Funding Level, 2012 110
Figure 7.1: Commercially Available Regenerative Products 119
Figure 7.2: Global Market for Tissue Engineering Products, 2012-2019 123
Figure 7.3: Global RM Market for Cardiology and Vascular Products, 2012-2019 126
Figure 7.4: Alternatives for Medtronic’s Infuse 128
Figure 7.5: Global Market for RM Products in Orthopedics, Musculoskeletal and
Spine, 2012-2019 130
Figure 7.6: Global RM Market for Neurology Products, 2012-2019 131
Figure 7.7: Global RM Market for Dental Products, 2012-2019 132
Figure 7.8: Global Tissue Engineering and Cell Therapy Market for Cancer
Products, 2012-2019 133
Figure 7.9: Global Market for RM Products in Urology, 2012-2019 134
Figure 7.10: Global Market for RM Products in Skin/Integument, 2012-2019 135
Figure 7.11: Global Tissue Engineering and Cell Therapy Market, 2012-2019 136
Figure 7.12: U.S. Market for Tissue Engineered Skin Replacement and Substitutes,
2012-2019 137
Figure 7.13: U.S. Market for RM Products in Orthopedic/Spine, 2012-2020 139
Figure 7.14: U.S. Market for RM Products in Nerve Repair, 2012-2020 140
Figure 7.15: U.S. Market for RM Products in Cardiovascular Therapies, 2012-2020
141
Figure 7.16: U.S. Market for RM Products in Anti-Inflammatory Therapies,
2012-2020 142
Figure 7.17: U.S. Market for RM Products in Diabetes, 2012-2020 143
Figure 7.18: U.S. Market for Regenerative Medicines, 2012-2020 144
Figure 7.19: U.S. Regenerative Medicine Market by Segment, 2020 145
Figure 8.1: Global Market for Stem Cell Products, 2012-2020 148
Figure 8.2: U.S. Market for Stem Cell Products, 2012-2020 151
Figure 8.3: Estimated U.S. Market for Stem Cell Therapy by Type, 2020 153
Figure 8.4: European Market for Stem Cell Products, 2012-2020 153
Figure 8.5: Number of Autologous and Allogeneic Cell Therapy Firms in Europe 154
Figure 8.6: Asia-Pacific Market for Stem Cells, 2012-2019 155
Figure 8.7: Global Autologous Cell Therapy Market, 2012-2019 156
Figure 9.1: Cell-Based Business Models 159
Figure 9.2: Current Autologous Business Models 161
Figure 9.3: Current Allogeneic Business Models 162
Figure 10.1: Aastrom’s Cell Expansion Process 167

INDEX OF TABLES

Table 2.1: Commercially Available Bioengineered Skin Products 23
Table 2.2: A Partial List of Companies Offering Bioreactor Systems 25
Table 2.3: Number of Tissue Engineering Companies in the Five Focus Countries 28
Table 2.4: Number of Tissue Engineering Firms Developing Stem Cells Seeded to
Scaffolds 28
Table 2.5: Number of Tissue Engineering Firms Focusing on Skin, Cartilage, Bone
and Urological
Products 29
Table 2.6: Number of Tissue Engineering Firms Focused on Cardiovascular Products
30
Table 2.7: Number of Tissue Engineering Firms Focusing on Neurological Products
30
Table 2.8: Number of Tissue Engineering Firms Focusing on Pancreas, Liver and
Kidney 31
Table 2.9: Number of TE Firms Focused on Autologous and Allogenic Products 31
Table 2.10: Major Cell Therapy Companies 36
Table 2.11: Geographical Distribution of Cell Therapy Companies 38
Table 2.12: Cell Therapy Products on the Market 40
Table 2.13: Cell Therapy Products on the Market by Type and Application 40
Table 2.14: Potential Patients for Cell Therapy in the U.S. 41
Table 2.15: Number of Patients Treated with Cell Therapy Between 1988 and 2010
42
Table 2.16: Cell Therapy Pipeline, 2005-2011 42
Table 2.17: Number of Stem Cell Clinical Trials by Indication, 2012 43
Table 2.18: Major Cell Therapy Clinical Trials for Diabetes and Estimated
Enrollment Targets, 2012 44
Table 2.19: Progress in Clinical Trials for Diabetes, 2012 44
Table 2.20: Cell Therapy Deals, 2007-2011 49
Table 2.21: Select Cell Therapy Products with FDA/EMA Regulatory Approval,
1998-2010 50
Table 2.22: Cell Therapy Companies and Products 50
Table 2.23: Cell Therapy Products Approved in South Korea 51
Table 2.24: Selected Suppliers of Culture Media and Reagents 58
Table 2.25: Selected Suppliers of In Vitro Te

To order this report:
: Regenerative Medicine Markets

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

RELATED LINKS
http://www.reportlinker.com

HARRISBURG, Pa., May 22, 2013 /PRNewswire-USNewswire/ — Both novice and experienced campers will find two promotional programs fueling new interests and activities as the Memorial Day weekend kicks off the traditional camping season at state parks across the state.

For the third year, the Department of Conservation and Natural Resources is partnering with Gander Mountain to provide first-time campers with needed gear and a reservation for two nights at participating state parks for just $20. Meanwhile, a new cooperative effort with The North Face will be offering staff-guided Family Camping Programs at parks; discounted park stays; and camper-oriented activity guides.

“Our state parks are busy rolling out the welcome mat for another fun-filled season and these two outdoors-oriented sponsors have offered a hand,” DCNR Secretary Richard Allan said. “Both programs encourage and promote park camping, offering first-timer help and equipment for some; special assistance for families; and costs savings for all.”

“The First Time Camper Program is being offered at 16 state parks across the state,” Allan said. “You can’t beat this offer as far as the cost and a chance to enjoy many other activities at our state parks such as hiking and fishing. A park staffer will even help you set up camp.”

Sixteen state parks are participating: Black Moshannon, Centre County; Caledonia, Franklin County; Chapman, Warren County; Colonel Denning, Cumberland County; Gifford Pinchot , York County; Hills Creek, Tioga County; Keystone, Westmoreland County; Lackawanna, Lackawanna County; Little Pine, Lycoming County; Locust Lake, Schuylkill County; Ole Bull , Potter County; Parker Dam , Clearfield County; Promised Land, Pike County; Raymond B. Winter , Union County; Ryerson Station , Greene County; and Sinnemahoning, Cameron and Potter counties.

Reservations can be made by calling the park office directly. The program runs from Memorial Day weekend through the summer.

Gear provided by Gander Mountain and DCNR includes a four-person tent; rain tarp; four sleeping pads; four camp chairs; flashlight; lantern; camp stove; and four hot dog/marshmallow sticks. The gear must be returned upon departure.

Participants will need their own food, cooking utensils and bedding. Suggested packing lists will be provided.

Family fun is the keystone of the partnership between DCNR and The North Face in which several state parks volunteered to offer staff-led, guided camping experiences from early June through early September. 

Seven state parks are participating in the Family Camping Program: Jacobsburg, Kings Gap, Ohiopyle, Pymatuning, Delaware Canal, Presque Isle and Yellow Creek.

“Visitors can look forward to an overnight camping experience in which we supply just about everything from cook stoves to needed supplies,” Allan said. “We’ll guide you the whole way — from setting up your tent and making dinner to leading you on a guided hike or kayak adventure.”

In addition, as part of this cooperative effort, an activity guide was created that focuses on state parks offering five outdoors pursuits:  camping, hiking, biking, wildlife viewing and play.  Both the guides and coupons for a $10 discount off the fee for a second night of state park camping will be given out to anyone purchasing The North Face gear or clothing at any The North Face store or authorized retailer in Pennsylvania.  

With 120 state parks covering about 300,000 acres, there is a state park within 25 miles of nearly every Pennsylvanian. The parks feature an array of recreational opportunities, provide a forum for multiple environmental education programs and conserve thousands of acres of unique natural areas, among many other features.

State parks also serve as economic generators to the communities that surround them, generating about a billion dollars annually in economic activity.

Details on the First Time Camper and Family Camping programs and information on Pennsylvania‘s state parks can be found at www.visitPAParks.com.

Media contact: Terry Brady , 717-772-9101.

SOURCE Pennsylvania Department of Conservation and Natural Resources

RELATED LINKS
http://www.dcnr.state.pa.us